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TRIAL PERSONNEL AND CONTACT DETAILS 
 
 
Sponsor: The University of Nottingham 
Contact name Mr Paul Cartledge 
Head of Research Grants and Contracts 
Research Innovation Services 
King’s Meadow Campus 
Lenton Lane 
Nottingham NG7 2NR 
 
 
 
Chief investigator: Professor Philip Bath 
(Medical expert) The Stroke Association Professor of Stroke Medicine 
BSc MBBS MD FRCPath FRCP FESC 
Phone: 0115 8231765 
Fax: 0115 8231767 
Email: Philip.Bath@nottingham.ac.uk 
 
 
Trial Coordinating Centre: Division of Stroke  
University of Nottingham 
Clinical Sciences Building 
City Hospital 
Hucknall Road Nottingham NG5 1PB 
Phone: 0115 8231671 
Fax: 0115 8230273 
Email: podcast@nottingham.ac.uk 
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SYNOPSIS 
Title Prevention of decline in cognition after stroke trial: a factorial 
randomised controlled trial of blood pressure and lipid lowering 
Short title Prevention Of Decline in Cognition After Stroke Trial (PODCAST) 
Acronym PODCAST 
Chief Investigator Professor Philip Bath 
Objectives Primary: To determine if ‘intensive’ blood pressure lowering 
therapy, and/or ‘intensive’ lipid lowering therapy, after stroke 
reduces cognitive decline and dementia. 
Secondary: To determine if ‘intensive’ blood pressure lowering 
therapy, and/or ‘intensive’ lipid lowering therapy, after stroke 
reduces poor quality of life, poor function, depression, stroke 
recurrence, vascular events, and death. 
Trial Configuration Prospective, randomised, open-label, blinded end-point, controlled, 
partial factorial, phase IV trial 
Setting Secondary care 
Sample size estimate Assuming overall significance !=5%, power 1-"=90%, rate of 
cognitive decline in ‘guideline’ BP group = 25% and ‘intensive’ BP 
group = 20% (absolute risk reduction 5%, relative risk reduction 
20%) at 5 years, we estimate a sample size of 3,400 participants 
for the whole trial (start-up and main phase). The lipid factor will 
assume the same relative risk reduction (20 %) but will have a 
lower statistical power (#86 %), as it will only involve participants 
with ischaemic stroke (#3,060) 
 
Number of 
participants 
3,400 participants (1,700 per BP group, ~1,530 per lipid group), 
comprising a: 
Start-up phase: 600 participants (300 per BP group, ~270 per 
lipid group) 
Main phase: 2,800 participants (1,400 per BP group, ~1,260 per 
lipid group) 
 
Eligibility criteria Ischaemic stroke or primary intracerebral haemorrhage 
3-7 months post stroke event 
Age>70 and normal cognition (“telephone-MMSE” >16), or 
Age 60-70 with “telephone-MMSE” 17-20/22 
 
Description of 
interventions 
BP lowering strategy: 
‘Intensive’ group – target SBP <125 mmHg 
‘Guideline’ group – target SBP <140 mmHg 
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Treatments will use licensed BP-lowering interventions (including 
life style modifications and drugs) 
 
2. Lipid lowering strategy: 
‘Intensive’ group – target LDL-cholesterol <1.4 mmol/l (or total 
cholesterol <3.1 mmol/l if LDL-cholesterol cannot be calculated) 
‘Guideline’ group –target LDL-cholesterol <3.0 mmol/l (or total 
cholesterol <5.0 mmol/l if LDL-cholesterol cannot be calculated) 
Treatments will use licensed lipid-lowering interventions (including 
life-style modification and drugs) 
Duration of trial 8 years. The proposed start date is September 2010 
Start-up phase: 3 years 
Main phase: 5 years 
 
Randomisation and 
blinding 
Randomisation over a secure internet site 
The trial is open-label with blinded end point 
 
Outcome measures Primary: Comparison of cognition (Addenbrooke’s Cognitive 
Examination-Revised extended to include death) between 
‘intensive’ and ‘guideline’ BP/lipid lowering groups 
Secondary: Other cognitive assessments; Quality of life; Vascular 
events; Functional outcome; Depression; Death 
 
Statistical methods Outcomes will be analysed by multiple regression, ordinal logistic 
regression and binary logistic regression, depending on the 
measure, with adjustment for baseline stratification and 
minimisation variables 
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ABBREVIATIONS 
ABPM Ambulatory Blood Pressure Monitoring 
ACEI Angiotensin Converting Enzyme Inhibitor 
ACE-R Addenbrooke’s Cognitive Examination-Revised 
AE Adverse Event 
ALLHAT Anti Hypertensive and Lipid Lowering Treatment to Prevent 
Heart Attacks Trial 
ALT Alanine transaminase 
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial 
AVM Arterio-venous malformation 
BHS British Hypertension Society 
BMI Body Mass Index 
BP Blood Pressure 
CADASIL Cerebral Autosomal Dominant Arteriopathy with Subacute 
Infarcts and Leukoencephalopathy 
CI Chief Investigator 
COPD Chronic Obstructive Pulmonary Disease 
CLRN Comprehensive Local Research Network 
CRF Case Report Form 
CSP Coordinated System for obtaining NHS Permissions 
CT Computer axial Tomography (scan) 
DMC Data Monitoring Committee 
ENOS Efficacy of Nitric Oxide in Stroke 
EMEA European Medicines Agency 
GCP Good Clinical Practice 
GP General Practitioner 
HbA1c Glycosylated haemoglobin test 
HR Heart rate 
HOT Hypertension Optimal Treatment Trial 
IQCODE Informant Questionnaire on Cognition Decline in the Elderly 
ICC International Coordinating Centre 
IIS Informant Information Sheet 
HDL High Density Lipoprotein 
LDL/LDL-c Low Density Lipoprotein-cholesterol 
MI Myocardial Infarction 
MMSE Mini mental status examination 
MRI Magnetic Resonance Imaging 
MRC Medical Research Council 
NHS National Health Service 
NICE National Institute of Health and Clinical Excellence 
NIHR National Institute for Health Research 
NINDS National Institute of Neurological Disorders and Stroke 
OCSP Oxford Community Stroke Project 
Od Once daily 
On At night 
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OAST Optimising Analysis of Stroke Trials collaboration 
OA-Cog Optimising the Analysis of Cognition collaboration 
PCT Primary Care Trust 
PI Principle Investigator 
PICH Primary Intracerebral Haemorrhage 
PIN Postal Index Number 
PIS Participant Information Sheet 
PP Pulse Pressure 
PRoFESS Prevention regime for effectively avoiding second strokes 
Study 
PROGRESS Perindopril pROtection aGainst REcurrent Stroke Study 
PSD Post-Stroke Dementia 
QOF Quality and Outcomes Framework 
ReDa Research Database 
REC Research Ethics Committee 
R&D Research and Development department 
RR Relative Risk 
RRR Relative Risk Reduction 
SAE Serious Adverse Event 
SBP Systolic Blood Pressure 
SHEP Systolic Hypertension in Elderly Program 
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol 
Levels  
STU Stroke Trials Unit 
Syst-Eur Systolic Hypertension in Europe Trial 
t-MMSE telephone mini mental status examination 
TC Total Cholesterol 
TG Triglycerides 
TMC Trial Management Committee 
TOAST Trial of Org 10172 in Acute Stroke Treatment Trial 
TSC Trial Steering Committee 
UE Urea and electrolytes 
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1 TRIAL OBJECTIVES AND PURPOSE 
1.1 PURPOSE 
Develop interventions to prevent cognitive decline and dementia after stroke. 
1.2 PRIMARY OBJECTIVE 
To determine if ‘intensive’ blood pressure lowering therapy, and/or ‘intensive’ lipid 
lowering therapy, after stroke reduces cognitive decline and dementia. 
1.3 SECONDARY OBJECTIVES 
To determine if ‘intensive’ blood pressure lowering therapy, and/or ‘intensive’ lipid 
lowering therapy, after stroke reduces poor quality of life, poor function, depression, 
stroke recurrence, vascular events, and death. 
2 TRIAL DESIGN 
2.1 TRIAL CONFIGURATION 
PODCAST is a multi-centre, prospective, randomised, open-label, blinded end-point, 
controlled, partial-factorial, phase IV trial. It will be performed in two phases: start-up 
and main. 
The start-up phase will recruit 600 participants from 30+ UK Stroke Research Network 
Centres in 3 years. Assuming a ‘go’ decision at 34 months based on start-up 
feasibility, as assessed by data collected from the start-up phase, the trial will 
seamlessly proceed into the main phase with the same design for a further 5 years. 
The main phase will aim to recruit a further 2,800 participants from across 100 sites 
internationally. Separate permission for funding from the appropriate bodies will be 
sought for the second phase (as done in the ENOS trial ISRCTN 99414122, with 
funding moving from BUPA Foundation to MRC). 
The start-up phase will assess feasibility in the UK: 
• Delivering the protocol 
• Recruiting 30+ centres and 600 participants 
• Achieving and maintaining differences in systolic BP (≧10 mmHg) and LDL-
cholesterol (≧1 mmol/l) between the ‘intensive’ and ‘guideline’ treatment 
groups 
• Performing clinic and telephone follow-up of outcome measures 
• Assess the sensitivity of ACE-R to change 
• Tolerability and safety of interventions 
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The main phase will assess efficacy with recruitment from both UK and international 
centres. Participants enrolled in the start-up phase will continue to be followed during 
the main phase. The trial is being discussed with other countries (including those 
taking part in the ongoing ENOS trial,(1) as well as France). Separate ethical review 
and permission will be sought in each participating country. 
If the overall trial is positive for one or both ‘intensive’ interventions, then they can be 
implemented readily and inexpensively in the UK since the treatments are available 
and will be off patent. 
2.2 OUTCOME MEASURES 
2.2.1 Primary outcome measure 
For each of BP-lowering and lipid-lowering arms, comparison between ‘intensive’ and 
‘guideline’ groups, of cognition, assessed using the Addenbrooke’s Cognitive 
Examination- Revised (ACE-R)(2), (a superset of the Mini-Mental State Examination, 
MMSE(3)). Certain memorable items in the ACE-R will be cycled at each time point - 
see working practice document. 
2.2.2 Secondary outcome measures 
For each of BP-lowering and lipid-lowering arms, comparison between ‘intensive’ and 
‘guideline’ groups: 
1. Dementia 
a. Using AD - NINCDS/ADRDA (4), VaD - NINDS-AIREN (5) and Dementia- 
ICD-10 
b. With/without recurrent stroke 
2. Cognition 
a. Global – MMSE, t-MMSE, TICS (6) 
b. Association – trail making A/B (7, 8) 
c. STROOP test (8) 
d. Cognitive decline with/without recurrent stroke 
e. Ordinal cognition (MMSE>28/23-28/10-22/<10/dementia/dead) 
f. IQCODE (by informant) (9) 
3. Quality of life – EuroQoL(10) 
4. Depression (Zung) (11, 12) 
5. Dependency (modified Rankin Scale, mRs) (13, 14) 
6. Disability (Barthel Index, BI) (14, 15) 
7. Stroke recurrence 
8. Myocardial infarction 
9. Composite vascular events (non-fatal stroke, non-fatal MI, fatal vascular) 
10. Stroke: fatal/severe non-fatal/mild/TIA/none(16) 
11. Myocardial infarction: fatal/non-fatal/angina/none (16) 
12. Vascular: fatal/non-fatal/none (16) 
13. Revascularisation (heart, limb, visceral/renal) or amputation 
14. New Diabetes 
15. New atrial fibrillation 
16. Residence (home, institution), care package, informal family support 
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17. Blood pressure (systolic BP, diastolic BP, pulse pressure, rate-pressure product) 
18. Lipids (TC, TG, HDL, calculated LDL) 
19. Neuroimaging (in a subset of participants) 
2.2.3 Safety outcome measures 
Comparison between ‘intensive’ and ‘guideline’ BP/lipid lowering groups: 
1. Death 
2. Falls (leading to fracture or hospitalisation) 
3. Symptomatic hypotension 
4. Myositis and rhabdomyolysis 
5. SAEs 
2.3 RANDOMISATION AND BLINDING 
2.3.1 Randomisation 
All participants eligible for inclusion and for whom consent has been obtained will be 
randomised centrally using a secure internet site in real-time. Randomisation will be 
performed using: 
1. Stratification on stroke type (ischaemic stroke/PICH) and country 
2. Minimisation on key prognostic/logistical baseline factors: 
a. Age (<70/>70 yrs) 
b. Sex (female/male) 
c. Dysphasia, mild (no/yes) 
d. ACE-R (>85/<85) 
e. Mean systolic blood pressure, sitting (<150/>150 mmHg) 
f. Total cholesterol (<4.0/>4.0 mmol/L) 
g. Function/dependency (mRS<1/>1) 
h. Brain region (subcortex/cortex) 
i. Evidence of periventricular white matter lucency (e.g.leukoaraiosis) (no/yes) 
j. Time since index stroke (<140/>140 days) 
k. Number of antihypertensive drugs (<2/>2) 
l. Already on a statin (no/yes)   
 
This approach ensures concealment of allocation, minimises differences in key 
baseline variables, and slightly improves statistical power.(17) 
In the event that the website cannot be accessed, participants may be randomised by 
telephoning one of a series of emergency telephone numbers. These participants will 
be randomised without stratification or minimisation. 
Confidential: PODCAST protocol, version 1.5, 28 February, 2012 
This protocol is confidential and the property of the University of Nottingham. No part of it may be 
transmitted, reproduced, published, or used by others persons without prior written authorisation from the 
University of Nottingham 
Page 12 of 75 
2.3.2 Blinding 
PODCAST is a trial of BP and lipid management post-stroke. Hence, it is not placebo-
controlled and neither participants nor investigators will be blinded to treatment. 
However, outcome assessment will be assessed blinded to treatment assignment. 
2.4 DURATION OF THE TRIAL AND PARTICIPANT INVOLVEMENT 
The start up phase will run for 3 - 4 years with participant recruitment from 30 UKSRN 
sites = 1 participant/site/month) with average follow-up 2 years (minimum 1 year). 
The main phase will then run for a further 4 - 5 years (total 8 years). Participant 
involvement in the whole trial will range from 1-8 years depending on the time of 
recruitment (See tables 1,2,3). 
Table 1: Trial timeline: Start-up phase 
Time (months) -6-0 0-2 3-6 7-18 19-24 25-30 31-36 
Protocol <>       
Approvals <>       
Trial materials <>       
Site identification < = >     
Funding, TSA/AS  < = = = = > 
Recruit participants  < = = = = > 
DMC reviews   < = = = > 
Feasibility reviews    < = = > 
Interim analysis (blinded)       <> 
Table 2: Trial timeline: Main phase 
Time (months) 37-
42 
43-
48 
49-
54 
55-
60 
61-
66 
67-
72 
73-
78 
79-
84 
85-
90 
91-
96 
Further site 
identification 
< = = = >      
Funding (source to 
be identified 
 < = = = = >    
Recruit participants < = = = >      
DMC reviews < = = = = = = = >  
Final data cleaning        < = > 
Analysis          <> 
Nb; Participants enrolled in the start-up phase will continue to be followed up in the 
main phase. 
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2.5 SELECTION AND WITHDRAWAL OF PARTICIPANTS 
2.5.1 Recruitment (see figure 4) 
Participants will be recruited from hospital-based stroke services. The initial approach 
will be from a member of the participant’s usual care team (which may include the 
investigator and/or research nurses). The investigator or their nominee, e.g. from the 
usual care team (including research team), will inform the participant about the trial 
and a participant information sheet will be provided. Patient and GP contact details 
will be collected. Informed consent will be taken from participants at this point of 
contact to perform a face-to-face assessment of cognition (“telephone-mini mental 
status examination”) and function (modified Rankin scale) at 8-26 weeks after the 
stroke. 
On the basis of the assessments, if the participant is eligible and interested, a 
participant information sheet, a substudy information sheet (if taking part), and 
informant information sheet, will be given to the participant; a blood test request form 
for fasting lipids, glucose, urea and electrolytes, and HbA1c will also be provided. The 
participant’s GP will be informed about the study and a ‘GP practice briefing sheet’ 
(with details of GP involvement in the trial) posted to them. Should the GP have 
concerns about their patient participating in the study, they will be asked to contact 
the local hospital research centre. It is important to note that GPs will not be involved 
in screening and recruiting patients and therefore will not require Good Clinical 
Practice (GCP) certification. 
Participants will be contacted a few days later to assess their views about participation 
in the trial and to answer any questions. If they have agreed, participants will be 
asked to have the blood test (for fasting lipids, glucose, urea and electrolytes, and 
HbA1c) done at their GP practice (with the blood test form provided). All participants 
and their informant (see Section 2.5.5) will be booked to come to the local hospital 
research centre for further discussion, and if agreeable, enrolment and randomisation 
into the study. There should be a minimum of 1 week between the screening 
assessment and randomisation, so as to give time for the GPs to report any concerns 
they may have regarding their patient participating in the study. It is assumed that 
most GPs will want to support their patients if they elect to take part in clinical 
research; however, if GPs refuse, such patients will be withdrawn from the trial.  
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Figure 4:Trial Flow Chart – actions prior to and at randomisation 
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† few - approximately 2-4 days 
 
Acronyms Inclusion criteria  
BP Blood pressure - 
GFR glomerular filtration rate 45 (eGFR37 in people of 
African/Afro-Caribbean origin)  
LDL-c LDL-cholesterol (fasting) - 
LFT liver function test ALT<3 times upper limit of 
normal, using local laboratories 
range 
mRs modified Rankin Scale <3 
mRsp pre-morbid modified Rankin Scale <3 
PIS Patient Information Sheet - 
SBP systolic blood pressure 125-170 mmHg 
TC total cholesterol (fasting) 3-8 mmol/l 
t-MMSE telephone Mini Mental State Examination >16/22 if age >70  
17-20/22 if age >60 
  
* Only applies to patients with prior ischaemic stroke 
** See management algorithms (intensive lipid and 
BP lowering working practice documents) 
 
 
2.5.2 Inclusion criteria 
1. Age>70 years and “telephone-MMSE” >16; or age >60 years and “telephone-
MMSE” 17-20/22 
2. Functionally independent (mRS 0-2) 
3. Ischaemic stroke .Strokes may be of any OCSP/TOAST type and in the anterior or 
posterior circulation. 
4. 3-7 months post-event (to allow cognitive,(18) neurological, BP and lipid(19) 
stabilisation, but avoid attrition) 
5. Systolic BP 125-170 mm Hg 
6. Total cholesterol 3-8 mmol/l 
7. Presence of an informant: partner, sibling, child, friend (for IQCODE) 
8. Capacity and willingness to give consent 
2.5.3 Exclusion criteria 
1. Participants not meeting inclusion criteria 
2. Subarachnoid haemorrhage 
3. Secondary intracranial haemorrhage (trauma, AVM, cavernoma) 
4. No CT/MRI within 10 days of index stroke 
5. Inability to give consent or do study measures, e.g. severe dysphasia, weakness of 
dominant arm 
6. Profound deafness 
7. Severe hypertension (systolic BP>170 mmHg) 
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8. Definite need for ‘intensive’ BP control 
9. Severe hypercholesterolemia (TC>8 mmol/l) 
10. Definite need for, or demonstrated intolerance of, ‘high intensity’ statin 
11. Definite need for a cholinesterase inhibitor 
12. Familial stroke associated with dementia, e.g. CADASIL 
13. Chronic renal failure: eGFR<45 (or eGFR<37 in people of African/Afro-Caribbean 
origin) 
14. Liver disease, ALT>3 times upper limit of normal, using local laboratories range 
15. Ongoing participation in trials involving drug (including CTIMP trials) and/or 
devices. Participants already in another trial may be screened for PODCAST, 
provided the participation in the other trial is complete, prior to PODCAST 
randomisation. 
16. Any serious medical co-morbidity (e.g. active malignancy) such that the life 
expectancy is <24 months 
17. Clinically unstable at the time of enrolment 
18. Dementia 
19. NYHA classification of 3 or 4  
 
2.5.4 Informed consent  
All participants must have capacity, and be willing and able to provide written 
informed consent. Participants will be screened for potential recruitment during their 
initial presentation to the hospital stroke services (see section 2.5.1). A participant 
information sheet will be provided explaining the study. Informed consent for 
screening will be taken at this point of contact for conducting the following 
assessments, 8 to 26 weeks after their stroke: 
(i) assessment of cognition (“telephone-mini mental status 
            examination”) 
(ii) assessment of function (modified Rankin scale) 
(iii) blood test for fasting lipids, glucose, urea and electrolytes, and HbA1c. 
If participants are eligible and interested, a participant information sheet, substudy 
information sheet (if taking part), and informant information sheet, along with a blood 
test form for fasting lipids, glucose, urea and electrolytes, and HbA1c will be given to 
them. (See figure 4 for trial flow chart, see Section 2.5.1 for details about 
recruitment). 
Participants will be contacted a few days later to assess their views and answer 
questions about the trial. All participants and their informant will be booked to come 
to the research clinic and, if agreeable, for enrolment and randomisation into the 
study. In the research clinic the investigator will further explain the details of the trial 
and answer any questions that the participant has concerning trial participation. 
The principal investigators and trial doctors, will decide if participants have the 
capacity to give consent at baseline by asking them the following series of questions 
to assess their understanding of the trial before taking consent. 
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1. What is the trial aiming to achieve? (Answer: if intensive treatment of high blood 
pressure and lipids will prevent cognitive decline) 
2. What are the two groups of intervention? (Answer: intensive and guideline) 
3. How long will treatment be continued? (Answer: 1-8 years) 
Potential participants who answer all the 3 questions correctly will be enrolled into the 
study. A signed and dated informed consent will be taken before the participant is 
recruited into the trial.  
Informed consent will be collected from each participant before they undergo any 
interventions (including physical examination and history taking) related to the trial. 
Signed consent forms will be kept by the Participant and Investigator, and in the 
participant’s hospital records. The GP will be informed if the participant agrees to join 
the trial. 
As assessment of cognitive impairment is one of the objectives of the trial, it is 
inevitable that some participants will lose the capacity to maintain consent for the 
duration of their participation. This will be explained to potential participants. Consent 
will be taken at enrolment, to continue in the trial, should participants lose the 
capacity to maintain consent during the trial. However, if a participant has lost 
capacity and the participant’s informant feels that continuing in the trial is not in the 
participant’s best interests, the informant can withdraw the participant from the trial. 
If needed, the usual hospital interpreter and translator services may be used to assist 
with discussion of the trial, the participant information sheets, and consent forms. But 
consent forms and information sheets will not be available printed in other languages 
since it will not be possible to do telephone or clinic outcome assessments in other 
languages. It will be explained to the potential participant that entry into the trial is 
entirely voluntary and that routine treatment and care will not be affected by their 
decision. It will also be explained that they can withdraw at any time but attempts will 
be made to avoid this occurrence. Withdrawal may comprise either withdrawal from 
treatment but with continuing follow-up, or withdrawal from both treatment and 
follow-up. In the event of withdrawal, it will be explained that existing data cannot be 
erased; consent to use this data in the final analyses will be sought, where 
appropriate. 
Should there be any major amendments to the protocol that might affect the 
continued participation in the trial by a participant and/or informant, consent will be 
obtained using an amended Consent form approved by the Research Ethics 
Committee, which will be signed by the participant and/or informant. 
2.5.5 Informant (Consultee) 
Availability of an informant (partner, sibling, child, friend) for the participant is a key 
inclusion criterion in the trial, as informant questionnaires (IQCODE) can give vital 
information about the participant’s cognition. If an informant can no longer fulfil their 
role (e.g. through death, or loss of capacity), then another informant will need to be 
consented. For this reason, two or more potential informants should be identified at 
baseline. It will be the aim to continue with a single informant as far as possible (see 
figure 5). 
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Figure 5 Algorithm for seeking consent from the participant and original informant, 
from one or more further informants if the earlier ones are no longer available, and 
from the participant and/or informant for major protocol changes. 
 
 
2.5.6 Expected duration of participant participation 
Trial participation will range from 1- 8 years depending on the time of recruitment. 
Long follow-up is essential in trials of cognition since cognitive impairment may take 
many years to develop. 
2.5.7 Removal of participants from therapy or assessments 
Participants may leave the trial for a variety of reasons, as detailed below. It should 
be noted that abrupt termination of trial treatment could affect the participant’s safety 
(e.g. hypertensive rebound) and administration of alternative treatment should be 
considered. 
2.5.7.1 Withdrawal of consent 
Participation in the trial is voluntary and participants are free to withdraw from the 
trial at any stage without giving a reason. However, if a participant wishes to 
withdraw, they will be requested to at least permit primary outcome data to be 
collected, ideally at the end of the follow-up period, ensuring that enough data are 
recorded to support the planned analysis. Participants won’t be accepted as lost to 
follow-up unless all attempted contacts have been fruitless, including: phone calls, 
letters, visits to their home, contact with their next of kin, and contact with their GP. 
Participants will be made aware (via the information sheet and consent form) that 
should they withdraw, the data collected up to the date of withdrawal cannot be 
erased and will be used in the final analysis. Participants who lose capacity during the 
trial may be withdrawn from the trial by their informant, if the informant feels that 
continued participation is not in the participant’s best interests. 
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2.5.7.2 Clinical need 
The participant’s primary physician is not blinded to treatment allocation and may 
remove, change or add to treatment if they feel this is clinically indicated (e.g. for 
reasons of safety or new information becoming available on the trial medication or 
condition being treated). 
2.5.7.3 Failure of participant to adhere to protocol requirements 
The Principal Investigator may remove the participant from the trial if they fail to 
adhere to the protocol through protocol violations and/or protocol deviations, and 
will be reported to the Chief Investigator of the trial centre. 
2.5.7.3.1 Protocol Violation 
A protocol violation is a deviation from the trial protocol where a participant is 
enrolled in spite of not fulfilling all the inclusion and exclusion criteria, or where 
deviations from the protocol could affect the trial delivery or interpretation 
significantly. 
The following baseline measures constitute a ‘protocol violation’: 
• Participant<60 years of age 
• “Telephone MMSE” score!16 
• “Telephone MMSE” score 21 if aged between 60-70 
• No index stroke 
• Randomisations <3 months or >7 months from onset of index stroke 
• Failure to obtain consent of participant 
• Participant with mRs >2 
• Failure to identify haemorrhagic stroke 
• Participant enrolled with known severe concomitant illness 
• Participant enrolled with known intracranial pathology other than stroke 
• Participant involved at time of randomisation in another medicinal and/or 
devices clinical trial 
• No brain imaging during index stroke event 
• No capacity to consent for the trial 
• Failure to meet the systolic BP inclusion criteria 
• Failure to meet the total cholesterol inclusion criteria  
• Absence of an informant 
The following practice during the trial constitutes a ‘protocol violation’: 
• Participant never receives ‘intensive’ BP lowering therapy when randomised to 
do so. 
• Participant never receives ‘intensive’ lipid lowering therapy when randomised to 
do so. 
• Failure to complete SAEs where appropriate 
• Annual clinic/telephone assessments are not performed. 
These lists of protocol violations will be updated, as necessary, in a Working Practice 
Document which will be uploaded and available on the trial website. 
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2.5.7.3.2 Protocol Deviation 
A protocol deviation is a minor deviation from the protocol that affects the conduct 
of the trial in a minor way. This includes any deviation from the trial protocol that is 
not listed as a protocol violation. 
The following practice during the trial constitute a ‘protocol deviation’ 
• Participant has no cranial imaging if they have another stroke. 
• Clinic or telephone assessments done outside the specified time by more than 
30 days. For the intensive BP group, clinic visits outside the specified time 
period by more than 14 days, or the time period between the visits is less than 
2 weeks. 
• Participant is not fully compliant with randomised treatment. 
These lists of protocol deviations will be updated, as necessary, in a working practice 
document which will be uploaded and available on the trial website. 
2.6 TRIAL TREATMENT AND REGIMEN 
Study participants will be randomised to: 
• Intensive or guideline BP lowering (all participants) 
• Intensive or guideline lipid lowering (ischaemic stroke only) 
As a result, patients can be randomised to one of 6 groups: 
• Intensive BP lowering and intensive lipid lowering (ischaemic stroke only) 
• Intensive BP lowering and guideline lipid lowering (ischaemic stroke only) 
• Guideline BP lowering and intensive lipid lowering (ischaemic stroke only) 
• Guideline BP lowering and guideline lipid lowering (ischaemic stroke only) 
• Intensive BP lowering only (intracerebral haemorrhage only) 
• Guideline BP lowering only (intracerebral haemorrhage only) 
The trial will assess management strategies (‘intensive’ vs. ‘guideline’), not particular 
drugs. All participants will receive lifestyle advice. Participants randomised to the 
guideline groups will be managed by their GP as per the current national/international 
guidelines and local practice. Participants in the intensive group will be managed by 
the local hospital research centre and medications initiated by either the local 
investigator or GP (following advice from the local investigator), and continued by the 
GP. The trial does not stipulate specific drugs but gives examples of these and 
relevant doses. The local hospital research centres and clinicians can use locally 
supported interventions as long as they fit with the overall design of the trial, i.e. 
intensive versus guideline BP and lipid lowering. 
2.6.1 Follow up visits 
All participants will be followed up every six months at the local hospital research 
centre; a blood form for fasting lipids, glucose, urea and electrolytes, and HbA1c will 
be posted to the participants 2-3 weeks prior to each clinic visit. They will be advised 
to have the test done, at their GP practice, 1-2 weeks prior to the visit, to aid 
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treatment decisions during the clinic visit. Cognition and other outcome data will be 
collected at the 6 month, 18 month, 30 month etc clinic visits (see section 2.2, 
appendices A-J). Cognition data will not be collected at the 12 month, 24 month, 36 
month clinic visits as all participants will also have telephone follow-up calls assessing 
cognition and dependency (see section 2.2, appendices C,D,F,G,H,I,J,) at 12 
months and then annually. The index event ECG will be collected at the Baseline visit 
and an ECG will be taken at the 6 month, 18 month, 30 month etc clinic visits. 
Participants in the intensive blood pressure group will have additional follow-up at 
one, two and three months after randomisation to monitor and modify treatment if 
necessary. These participants will be provided with a blood test form for U&E (urea 
and electrolytes) at: baseline, one month and two month visits, and advised to have 
the test at their local GP practice, 1-2 weeks prior to the next clinic visit. Rapid 
escalation and continuing intensive maintenance treatment is vital to ensure that a 
long-term difference in SBP of at least 10 mmHg is present between the treatment 
groups. 
Participants in the intensive lipid-lowering group will have an additional follow-up at 
three months after randomisation to monitor and modify treatment if necessary. 
These participants will be provided with a blood test form for lipids at the baseline 
visit and advised to have the test done at their local GP practice, 1-2 weeks prior to 
their 3 month visit. 
At formal research clinic appointments, if an intensive patient is found to have BP  
and/or lipid readings above the specified trial targets please bring them back to a 
‘floating’ appointment. This should be at 1 month post clinic. The follow-up comprises 
assessment of the latest BP and/or lipid levels, current medications, any recent 
adverse events, and any new other medical history. Subject to these, treatment 
should be escalated. 
The following data collected during clinic follow-up visits will be fed back to the GPs by 
the PODCAST ICC annually, as they also qualify as ‘Quality and Outcomes Framework 
(QOF)’ indicators: type of stroke, presence of myocardial infarction, angina, heart, 
failure, atrial fibrillation, dementia, depression, asthma or COPD (chronic obstructive 
pulmonary disease); BP, BMI (Body Mass Index), cholesterol levels, eGFR (estimated 
glomerular filtration rate); list of participant’s medications such as antihypertensive 
medications, lipid lowering agents, antiplatelets and anticoagulants; smoking status, 
advice on smoking cessation and dietary changes. Prior consent will be taken from all 
participants to share this information with their GPs.   
2.6.2 BP lowering arm 
 The composition of antihypertensive agents will vary between participants since the 
drugs are often used for other indications (e.g. 'A'/'B' post MI) and have 
contraindications (e.g. avoid 'A' in bilateral renal artery stenosis, avoid ‘B’ in asthma). 
The aim is to maintain a difference in SBP >10 mmHg between the randomised 
treatment groups of ‘intensive’ versus ‘guideline’ BP management. All participants will 
receive advice on salt restriction. 
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The following notes are only a guide and investigators may choose to differ, based on 
local policy, individual practice and patient specific characteristics.  
Antihypertensive drugs will be chosen according to the NICE/BHS ‘A (B)/CD’ guideline 
(CG34) where:(20) 
• A = angiotensin converting enzyme inhibitor (ACE-inhibitor, e.g. lisinopril 5-20 
mg od, perindopril 2-8 mg od, ramipril 1.25-5 mg bd) or angiotensin receptor 
antagonist (ARA, e.g. losartan 25-100 mg od, candesartan 8-32 mg od) 
• B = ß-receptor antagonist (e.g. atenolol 25-100 mg od, bisoprolol 5-20 mg od) 
• C = calcium channel blocker (e.g. amlodipine 5-10 mg od, nifedipine LA 30-60 
mg od, diltiazem, verapamil SR) 
• D = diuretic (e.g. bendroflumethiazide 2.5 mg od, hydrochlorothiazide 12.5 mg 
od) 
Participants should be started on either (provided there are no contraindications): 
• An ‘A’ drug, with subsequent addition of a ‘C’ then ‘D’ drug (as required); or 
• A ‘C’ drug, with subsequent addition of an ‘A’ then ‘D’ drug (as required) 
Additional drugs may be added from other classes: 
• Potassium sparing diuretics (e.g. spironolactone 12.5-100 mg od,(21) amiloride 
5-20 mg od) 
• "-receptor antagonists (e.g. doxazosin 4-16 mg od) 
• Centrally acting drugs (e.g. moxonidine 200-600 #g daily in divided doses) 
• ‘B’ drugs (e.g. atenolol 25-100 mg od) 
 
Investigators may choose to increase the dose of existing drugs (although this can be 
associated with adverse events and only moderate further reductions in BP) or add 
drugs from additional classes. ‘Long acting’ drugs should be chosen in preference to 
those which need twice/thrice daily dosing.  
The following advice will be updated as a ‘Working Practice Document’, on the trial 
website.  
• Start drugs at medium, not high, dose. The dose should be increased 2-4 weeks 
later for additional BP effect although side effects become more prominent as 
doses tend to the maximum. 
• Start with the lowest dose in very elderly patients or those with heart failure. 
• Alternatives to the suggested drugs listed above may be used according to local 
practice and formulary availability. 
• Consider escalating drug doses in between trial visits so as to accelerate control 
of blood pressure, i.e. write prescriptions with 2-4 weeks of one dose then with 
2-4 weeks at the next dose up. 
• Always treat clinical dehydration/hypovolaemia before adding drugs or 
increasing doses so as to avoid significant hypotension. 
• If ‘A’ or ‘K’ drugs are added, check renal function (U&E/BUN) after 1 week. 
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• If eGFR <45 (<37 in people of African/Afro-Caribbean origin) after addition of 
‘A’, stop ‘A’ and use alternative strategy. 
• If potassium >5.5 mmol/l after addition of ‘A’ or ‘K’, stop this and use 
alternative strategy. 
• If sodium <130 mmol/l after addition of ‘D’, stop it and use alternative strategy. 
• Specific drug classes may be indicated according to the presence of co-
morbidities: 
• Post myocardial infarction – consider ‘A’ and/or ‘B’ 
• Diabetes mellitus – consider ‘A’ 
• Specific drug classes are contra-indicated in the presence of known co-
morbidities: 
• Asthma – avoid ‘B’ 
• Renal artery stenosis (bilateral if 2 kidneys, unilateral if 1 kidney) – avoid ‘A’ 
• Consider referring compliant patients with uncontrolled/partially controlled 
high BP (i.e. SBP>160 on 3 or more BP lowering agents) to a specialist 
Hypertension clinic for specific investigation of secondary causes. 
• If cough or angioedema develops on ACE-I, switch to angiotensin receptor 
antagonist (ARA), e.g. losartan. 
• If bronchospasm develops on ‘B’, switch to another drug class as per 
management algorithm. 
• Significant postural hypotension, which may be symptomatic, may occur if 
adding ‘A’ to ‘D’. 
• Do not use rate limiting ‘C’ (verapamil) with ‘B’ (ß-RA). 
• Only wean down drugs/doses because of symptoms, not because of BP levels. 
• If uncertain, always check in the hospital/community/national drugs formulary 
regarding doses, indications and contra-indications. 
2.6.2.1  ‘Intensive’ BP treatment group 
The target is a systolic BP (SBP) of <125 mmHg. The intensive BP treatment 
algorithm (see working practice document), taking account of NICE guidelines 
relating to Stroke (CG68), Hypertension (CG34) and type 2 diabetes (CG66), will be 
provided to aid investigators in treatment decision-making so that target SBP of <125 
mmHg may be achieved. The algorithm is only a guide and investigators can choose 
other medications depending on local policy and practice. It will be updated, as new 
information becomes available on BP management, as a working practice document 
and mounted on the trial website. Following on from the NICE/BHS A(B)/CD rule, it is 
likely that participants randomised to the intensive group will receive 3 or more drugs 
and that additional agents will include agents such as doxazosin, spironolactone etc. 
Drugs will be weaned down if participants develop symptomatic hypotension. 
2.6.2.2 ‘Guideline’ BP treatment group 
The target systolic BP for the ‘guideline’ BP group is <140 mmHg (NICE CG 34). Drug 
therapy will typically include an 'A' and/or 'D' agent.(22) Monitoring and treatment for 
this group will occur in general practice to reflect current community-based practice 
based on national/international guidelines. 
2.6.2.3 Blood pressure measurement 
As a central aim of this trial is to ascertain the effect of lowering blood pressure 
immediately post stroke, it is vital that BP is measured in an accurate, reproducible, 
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unbiased, and validated manner. Measurements made using routine ward/clinic 
mercury or aneroid sphygmomanometers, or most semi-automatic devices, are not 
sufficient in these respects. 
All BP measurements should be performed using a validated automated blood 
pressure monitor, e.g. Omron 705CP or 705CP II. These devices have been validated 
by the British Hypertension Society,(23) in contrast to some other automated devices 
which have not been found to be accurate or reliable, and were used in the recent 
positive ASCOT hypertension trial involving 20,000 patients.(24) Baseline and follow-
up systolic and diastolic blood pressure and heart rate data are taken (4  
measurements taken in rapid succession) in the non-paretic arm with the participant 
sitting (3 readings) and standing (1 reading) entered on the baseline form. BP and 
heart rate readings should be printed out using the monitor printer and attached to 
the BP ‘print-out’ sheet. The times of last antihypertensive drug ingestion and BP 
measurement will be recorded on the clinic forms. Two BP monitors will be supplied to 
each centre and should only be used for participants in the PODCAST trial. BP 
monitors will be checked by staff from the PODCAST ICC during site visits; if broken 
or inaccurate, the monitor will be recalibrated or replaced. 
Further information on intensive blood pressure management is given in a working 
practice document. 
2.6.2.4 Ambulatory blood pressure monitoring (ABPM) 
In centres with the necessary ambulatory blood pressure monitoring equipment (e.g. 
SpaceLabs 90207), participants will have 24 hour ABPM (25) performed at 
recruitment and at all future scheduled clinic appointments. ABPM data will provide 
detailed information on: 
• BP and heart rate (HR) levels on treatment 
• BP and HR profile over 24 hours (peak and trough effects) 
• BP and HR variation (standard deviation) 
ABPM data will be printed out and faxed to the PODCAST International Coordinating 
Centre. Other haemodynamic variables are also related to stroke and recurrence and 
these will be derived from BP and HR:(26, 27) 
• Pulse pressure (PP)   = Systolic BP – diastolic BP 
• Mean arterial pressure (MAP) = Diastolic BP + (PP / 3) 
• Pulse pressure index (PPI)  = PP / MAP 
• Rate-pressure product (RPP) = Systolic BP x HR 
Data will be analysed with adjustment for baseline measurements. 
2.6.2.5 Treatment of sustained severe high BP 
If participants develop severe high BP (systolic BP >160 mmHg), treatment should be 
increased as per the BP algorithm. 
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2.6.2.6 Treatment of sustained low/low normal BP 
If participants develop symptomatic hypotension, treatment should be weaned down 
as per the BP algorithm. This will normally involve stopping the last added drug (i.e. 
‘last in/first out’). 
2.6.3 Lipid lowering arm (ischaemic stroke only) 
Lipid lowering agents will include statins and ezetimibe, e.g. as per UK NICE 
guidelines.(28-30) Only participants with an ischaemic stroke will be included in the 
lipid lowering arm since statins may be associated with intracerebral haemorrhage 
(31) due to mild antiplatelet properties. The aim is to maintain a difference in LDL-
cholesterol >1.0 mmol/l between the treatment groups. 
2.6.3.1 ‘Intensive’ lipid treatment group 
The target is a LDL-cholesterol (LDL-c) of <1.4 mmol/l (or total cholesterol <3.1 
mmol/l if LDL-cholesterol cannot be calculated, e.g. because of high triglyceride 
levels). Participants will receive repeat advice to take a plant stanol/sterol (as a 
spread or drink) as part of meals. The research clinic staff will monitor and prescribe 
medications using the intensive lipid treatment algorithm (see working practice 
document) as a guide and recommend to the general practitioner to continue 
treatment unless there is a medical reason to change it. 
At the baseline research clinic, and unless the LDL-cholesterol is <1.4 mmol/l, 
participants should, ideally, be started on, or switched to, a ‘high intensity’ statin (e.g. 
atorvastatin $40 mg,(28, 32)). Ezetimibe (10 mg od (29)) may be added at 
subsequent clinics if the LDL-cholesterol >1.4 (or total cholesterol >3.1 mmol/l if LDL-
cholesterol cannot be calculated). The algorithm will be updated, as new information 
becomes available on lipid management, as a working practice document and 
mounted on the trial website. 
Rapid escalation and continuing intensive maintenance treatment is vital to ensure 
that a long-term difference in LDL-c of at least 1.0 mmol/l (or TC of at least 1.0 
mmol/l) is present between the treatment groups. Drugs will be weaned down if 
participants develop symptoms. 
2.6.3.2 ‘Guideline’ lipid treatment group 
The target LDL-cholesterol for the ‘guideline’ lipid group is <3.0 mmol/l (or total 
cholesterol <5.0 mmol/l if LDL-cholesterol cannot be calculated). Participants will 
receive advice to take a plant stanol/sterol spread on bread at baseline. Drug therapy 
will typically comprise a ‘guideline’ statin, e.g. simvastatin range 10-40 mg on,(33) 
pravastatin 10-40 mg on, fluvastatin 10-80mg on - see NICE lipid guideline CG 67, 
2008.(28) Monitoring and treatment for this group will occur in general practice to 
reflect current community-based practice based on national/international guidelines. 
2.6.3.3 Lipid measurement 
Fasting lipids will be measured at an (provisionally) accredited Clinical Biochemistry 
laboratory proximal to the recruiting hospital and GP. Fasting should be performed 
overnight and measurements should be made at least 1 month after the last change 
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in lipid lowering therapy. Lipid measurement will utilise standard techniques and 
comprise: 
• Total cholesterol 
• Triglyceride 
• HDL cholesterol 
• LDL cholesterol (calculated) 
 
Further information on intensive lipid lowering is given in a working practice 
document. 
 
2.6.4 Monitoring interventions 
A member of the PODCAST ICC staff will monitor recorded BP and lipids in individual 
participants, unblinded to therapy, and suggest dose/drug escalation/weaning based 
on the BP/lipid algorithms to the local investigator/GP for the intensive BP and lipid 
groups. Their aim will be to ensure that BP/lipid levels are appropriate for the 
participant’s randomisation. In addition, all participants randomised to the intensive 
BP and lipid groups will have regular central telephone reminders to reinforce 
treatment assignment. 
The Trial Management Committee will monitor BP and lipid levels, and treatment 
crossovers, for each treatment group, i.e. unblinded to therapy. The TMC will report to 
the Trial Steering Committee at least 4 monthly on the magnitude of separation in BP 
and lipid levels between the treatment groups. The DMC will also report to TSC on 
their observations of separation in BP and lipid levels between the treatment groups. 
[Note: It is acceptable for trialists to un-blind themselves to surrogate outcomes such 
as BP to ensure that trial protocols are working, as done in HOT (34, 35)and MRC 
ENOS.(1)] 
2.6.5 Other secondary vascular prophylaxis 
All participants with stroke should receive standard life style advice and rehabilitation 
(as per NICE CG 68, 2008),(36) including: 
• Diet – calorie, salt, alcohol 
• Exercise 
• Smoking cessation 
• Rehabilitation (e.g. physiotherapy, occupational therapy, speech & language 
therapy, as required 
• Psychological assessment and therapy 
• All participants with ischaemic stroke should receive standard secondary 
prophylaxis (as per NICE CG 68, 2008),(36) including: 
• Oral anticoagulation, if a cardioembolic source of stroke is suspected 
• Antiplatelet agents (e.g. combined aspirin 50-81 mg od and dipyridamole MR 
200 mg bd) 
• Carotid endarterectomy for ipsilateral severe internal carotid artery stenosis 
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All concomitant treatments will be documented on the Case Report Form (CRF) and 
also in the participant's medical record, including any changes to these treatments. 
2.6.6 Blood Biomarkers and Pharmacogenetics Substudy 
Tertiary questions in PODCAST include assessing the effects of the interventions on 
blood biomarkers, and by participant’s genotype. These blood measures are optional. 
Centres who wish to participate in the blood biomarker study should have appropriate 
storage facilities including access to a centrifuge and freezer. 
Blood samples will be taken at baseline (4 ml into EDTA, 8 ml clotted). If it is not 
possible to take a blood sample at enrolment, both clotted (8 ml) and EDTA (4 ml) 
samples will be taken at the next feasible follow-up clinic visit. Clotted (serum) 
samples should be centrifuged prior to freezing; the EDTA samples should be frozen 
without centrifugation. Blood samples should be anonymised (identifiable by the 
centre number, participant trial number, participant initials, and date of sample) and 
stored locally in a freezer at -20oC (or lower if possible at -60oC to -80oC) and 
accounted for using the Blood Sample Freezer Log. The PODCAST ICC at Nottingham 
will arrange transfer of blood samples to Nottingham UK, for analysis. Blood samples 
will be destroyed once analysis is completed, this being dependent on the trial’s 
completion date. Samples will not be sold to third parties. 
2.6.6.1  Soluble markers of outcome and efficacy 
The exact identity of blood biomarkers will depend on developing knowledge on what 
may most usefully be measured. Examples include markers of vasomotor activity, 
lipid metabolism, thrombosis and inflammation. 
2.6.6.2 Genetic studies 
The exact identity of genetic markers will depend on developing knowledge of what 
may most usefully be measured. Examples include genes related to Apo-E, 
mechanism of action of drugs, lipid metabolism, thrombosis and inflammation. 
However, genetic methodology is evolving rapidly and it is not possible presently to 
say what approaches will be sued. 
The consent form will allow the participant to opt-in to the genetic substudy. 
Participants may continue in the overall trial, even if they elect not to consent to the 
genetics substudy. The participant may request destruction of the genetic samples at 
any time after consent and prior to creation of an anonymised database. 
2.6.7 Neuroimaging Substudy 
Cerebral white matter lesions (WML) have been associated with cognitive impairment 
in demented and non-demented elderly subjects. Whether lesion progression parallels 
this decline over time and whether treatment can modify this is less clear. 
Separate funding is being sought to perform systematic neuro-imaging in a subset of 
participants. All participants will be invited to take part in the imaging sub study. All 
participants will have a base line scan (done as part of routine clinical care at or soon 
after the index stroke), and is an inclusion criteria for the study. Participants will have 
an additional scan, as part of the imaging substudy at the end of 3 years. An MRI scan 
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of the brain will be the preferred imaging method for the additional scan, as it is more 
informative of cognitive change. However, where MRI cannot be performed, a CT scan 
of the brain will be done. A typical x-ray dose for a CT brain scan is 1.5 mSv, but due 
to variation in protocols, machines and patient size, this may reach 5mSv per scan. 
The consent form will allow the participant to opt-in to the neuro-imaging substudy. 
Participants may continue in the overall trial, even if they elect not to consent to the 
neuro-imaging substudy.  
3 STATISTICS 
A medical statistician will support the TSC with analyses. An interim analysis will be 
done during the start-up phase to demonstrate feasibility of the trial, recruitment of 
centres and participants, whether sufficient on-treatment differences in BP and lipids 
are obtained and maintained, and whether cognition is being assessed satisfactorily. 
Interim analysis of cognitive measures and vascular events during the start-up phase 
will be blinded to treatment assignment. 
3.1 Minimisation of bias 
As the trial is based on management strategies, placebo-control is not relevant. 
Sources of bias will be minimised with: 
• Central randomisation/concealment of allocation/data registration with real-time 
validation using an internet-based database 
• Blinded telephone/clinic assessment of cognitive/vascular outcomes 
• Blinded central adjudication of cognition/dementia and vascular events 
• Assessment of participant recall of treatment groups (‘intensive’, ‘standard’) at 
end of trial 
• Exclusion of participants enrolled in other drug trials 
• Analysis by intention-to-treat with adjustment for stratification/minimisation 
factors, number of BP-lowering treatments and use of ezetimibe 
3.2 Methods of analysis 
3.2.1 Primary outcome 
Comparison of cognition (ACE-R extended to include death) between ‘intensive’ and 
‘guideline’ BP/lipid lowering groups. The proportion of participants with cognitive 
impairment or who have died will be compared between the treatment groups, as 
done previously for MMSE (a subset of ACE-R).(33, 37) 
Analyses will be adjusted for baseline stratification variables (see section 2.3.1) and 
minimisation variables (see section 2.3.1) 
3.2.2 Analysis of cognition data 
Analyses based on binary outcomes are likely to be sub-optimal since dichotomisation 
of ordered categorical or continuous data is statistically inefficient, as seen in the 
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‘Optimising Analysis of Stroke Trials’ collaboration for functional outcome after 
stroke.(38-40) 
As a result, we are comparing, in the ‘Optimising the analysis of cognition’  
collaboration (OA-Cog), ordinal and binary approaches using individual patient data 
from existing dementia and vascular trials where cognition was recorded; if this shows 
that ordinal approaches are statistically more efficient, we will change the analysis of 
cognition to use such an approach (see figure 8) illustrates how an ordered 
categorical scale may be created from cognition data. 
 
Figure 8 Ordinal cognition scale using data from PROGRESS.(41, 42) 2000 patients 
without cognitive impairment (of the total ~3,300 patients) have been removed 
from each treatment group to make the illustration of cognition more clear. 
Perindopril-based BP lowering shifted patients from dementia/dead to no or some 
cognitive dysfunction (Mann-Whitney U, p=0.021, Bath P, unpublished). 
Methods of analysing cognition vary considerably. The OA-Cog project will use existing 
BP/cholesterol-cognition trial data to optimise statistical approaches (as we did with 
stroke (38-40)) with comparison of: 
• Gradient (42) 
• Mean cognition (41, 43, 44) 
• Median cognition 
• Mean change in cognition (43, 45-48) 
• Ordinal cognitive score (see figure 8) 
Analysis of the primary outcome will use the optimum approach once this has been 
identified. Additionally, techniques will be compared for dealing with participants who 
die: 
• Assign ACE-R score=-1 
• Use last cognition score carried forward 
• Calculate gradient of cognition scores,(42) assuming both linear and curvilinear 
models 
• Create an ordered categorical scale from data on cognition, dementia and death 
(see figure 8) 
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Dementia will be analysed as: 
• Proportions (37) 
• As part of an ordered categorical scale (see figure 8) 
Differential dropouts will also be assessed.(49) 
The final analysis will be described in detail in a statistical analysis plan, available on 
the trial website. 
 
3.2.3 Other outcomes 
Secondary and safety outcomes will be analysed using multiple regression, ordinal 
logistic regression or binary logistic regression, depending on the type of data. Where 
possible, dichotomous outcomes will be converted into ordinal outcomes (as in figure 
8) Analyses will be adjusted for the covariates as listed in section 2.3.1 since this 
approach increases statistical power (40) and is recommended by EMEA (‘Points to 
consider’).(50) 
3.3 Sample size and justification 
3.3.1 Start-up phase 
Recruitment of 600 participants (300/BP group, ~270/statin group) will be sufficient 
to demonstrate adequacy in recruitment of centres and participants, whether 
sufficient on-treatment differences in BP and lipids can be obtained and maintained, 
and whether cognition can be assessed satisfactorily. No formal sample size 
calculation is relevant to this part of the trial. 
3.3.2 Main phase 
Currently, ACE-R will be analysed as combined cognitive impairment or death using 
logistic regression; however the intention is to change this to an approach which 
optimises statistical power, depending on the results of the OA-Cog study (as 
discussed in section 3.2.2). The whole trial (start-up + main phases) will need a 
sample size of 3,400 (1,700 per group) post-stroke participants, assuming: 
• Significance, " = 5% 
• Power (1-ß) = 90% 
• Rate of cognitive impairment or death in guideline’ BP group = 25% at 5 years 
(main trial, average length of follow-up 4 years) [34] 
• Rate of cognitive impairment or death in ‘intensive’ BP group = 20%, i.e. 
absolute risk reduction (ARR) = 5% (number-needed-to-treat = 20), relative 
risk reduction (RRR) = 20% 
• Losses to follow-up = 3% 
Hence, 765 participants (0.225 x 3,400) will need to develop cognitive impairment or 
die. The sample size allows a smaller but clinically worthwhile decline in cognitive 
decline to be identified with 80% power, i.e. ARR = 4.5% (RRR 18%). Since there are 
less existing data on the effect of cholesterol lowering on cognition, the statin factor 
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will assume the same RRR (20%) but have less power (~86%) since it will only 
involve participants with ischaemic stroke (~3,060). 
Changing from a binary to ordinal analysis of the primary outcome may allow for a 
reduction in sample size of up to 30%, as seen in the ‘Optimising Analysis of Stroke 
Trials’ collaboration for functional outcome after stroke.(38-40) Providing, ordinal 
analysis appears to be more efficient than binary analysis for cognition data, the trial 
will be re-sized according to the method of Whitehead.(51) Any such change will be 
performed prior to database lock, blinded to treatment, and defined explicitly in the 
Statistical Analysis Plan. 
3.4 Definition of populations analysed 
3.4.1 Safety Set 
All randomised participants. 
3.4.2 Full Analysis Set (FAS) 
All participants in the Safety Set, and who took at least one treatment dose, and for 
whom at least one post-baseline assessment of the primary endpoint (ACE-R and vital 
status) is available. Participants in the FAS will be defined prior to database lock. 
3.4.3 Per Protocol Set (PPS) 
All participants in the Full Analysis Set, and who are deemed to have no protocol 
violations (i.e. no severe deviations that might have interfered with the objectives of 
the trial). Participants in the PPS will be defined prior to database lock. 
3.4.4 Analyses 
Efficacy will be assessed using the Full Analysis Set; secondary analyses will also 
assess efficacy in the Per Protocol Set. Safety summaries will be performed on the 
Safety Set. Major protocol deviations will lead to exclusion of a participant from the 
Per Protocol Set. 
3.5 Health economic analysis 
The impact of ‘intensive’ BP and lipid lowering on quality of life will be assessed using 
the EuroQoL. A full health-economic analysis will be performed as part of the trial and 
will cover measurement of service use, including costs of dementia/cognitive 
impairment, costs of excess treatment, cost/event (cognitive decline) prevented and 
cost/QALY. 
3.6 Potential analysis issues 
3.6.1 Falling event rates 
Event rates are often seen to be falling and lower than expected in vascular 
prevention trials, this often requiring recruitment of more participants and/or 
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prolongation of follow-up. The main issue in cognition/dementia studies is to ensure 
adequate length of follow-up, i.e. 5 years or more, so that cognitive impairment has 
time to develop. These issues will be monitored during the trial. 
3.6.2 Adequate BP/lipid effects 
The only large intensity BP trial (HOT (34, 35)) did not achieve its target BP 
differences. The start-up phase will check that differences in BP/lipids can be 
maintained; Participants in the intensive BP/lipid lowering groups will receive 
reminders about treatment during each clinic and telephone follow-up. Secondary 
observational analyses will assess the relationship between individual changes in 
BP/lipids and cognition. 
3.6.3 Guideline drift 
Guidelines may change over the life of the trial such that guideline BP and lipid targets 
could be reduced with time. In contrast, cost and participant resistance to taking 
multiple interventions may oppose this trend. The trial will monitor and adapt to such 
changes if detected. 
3.6.4 Analysis of cognition 
Methods for analysing cognition vary considerably and those using binary approaches 
may be sub-optimal. We have set up an international collaboration using existing 
BP/cholesterol-cognition trial data to optimise statistical approaches, as discussed in 
section 3.2.2, which will improve statistical efficiency thereby allowing a reduction in 
sample size. 
4 ADVERSE EVENTS  
4.1 Definitions 
4.1.1 Adverse Event 
An adverse event (AE) is defined as any unfavourable and unintended sign including 
an abnormal laboratory finding, symptom or disease associated with the use of a 
medical treatment or procedure, regardless of whether it is considered related to the 
medical treatment or procedure, that occurs during the course of the study. 
4.1.2 Adverse reaction 
An adverse reaction (AR) is any untoward and unintended response in a participant to 
a drug, which is related to any dose administered to that participant. Serious Adverse 
Event (SAE) or Serious Adverse Reaction (SAR) 
4.1.3 Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) 
Any adverse event or reaction occurring following trial-mandated procedures, having 
received BP and/or lipid lowering therapy, that results in any of the following 
outcomes: 
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1. Death 
2. A life-threatening adverse event 
3. Inpatient hospitalisation or prolongation of existing hospitalisation 
4. A disability / incapacity 
5. A congenital anomaly in the offspring of a participant 
6. Important medical events – these are events which are not fatal, life-threatening, 
or require hospitalisation, but nevertheless may jeopardise the participant and may 
require medical or surgical intervention to prevent one of the other outcomes listed 
above 
4.1.4 Suspected Unexpected Serious Adverse Reactions (SUSAR) 
SUSARs are serious adverse reactions, which are serious (as defined for SAEs), and 
unexpected (i.e. they are not recognised reactions for the trial medications).  
4.1.5 Serious versus severe adverse events 
A distinction is drawn between serious and severe adverse events. Severity is a 
measure of intensity whereas seriousness is defined using the criteria above. Hence, a 
severe adverse event need not necessarily be serious (e.g. most severe headaches 
are not serious).  
4.2 Causality 
The relationship between clinical events, including laboratory test abnormalities, and 
treatment will be assigned by the Investigator as follows: 
4.2.1 Not related or improbable 
Clinical event, including laboratory test abnormality, with a temporal relationship to 
trial treatments which makes a causal relationship incompatible or for which other 
treatments, chemicals or disease provide a plausible explanation. This will be counted 
as ‘unrelated’ for analysis purposes. 
4.2.2 Improbable 
Clinical events, including laboratory test abnormalities, with a temporal relationship to 
trial treatments which makes a causal relationship unlikely, or for which other 
treatments, chemicals or disease provide a plausible explanation. This will be counted 
as ‘unrelated’ for analysis purposes. 
4.2.3 Possible 
Clinical events, including laboratory test abnormalities, with a temporal relationship to 
trial treatments which makes a causal relationship a reasonable possibility, but which 
could also be explained by other treatments, chemicals or concurrent disease. This 
will be counted as ‘unrelated’ for analysis purposes. 
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4.2.4 Probable 
Clinical events, including laboratory test abnormalities, with a temporal relationship to 
trial treatments, which makes a causal relationship a reasonable possibility, and is 
unlikely to be due to other treatments, chemicals or concurrent disease. This will be 
counted as ‘related’ for analysis purposes. 
4.2.5 Definite 
Clinical events, including laboratory test abnormalities, with a temporal relationship to 
trial treatment administration which makes a causal relationship a reasonable 
possibility, and which can definitely not be attributed to other causes. This will be 
counted as ‘related’ for analysis purposes. 
4.3 Recording and Safety Reporting 
4.3.1 Adverse events  
AEs will not be recorded or reported due to their high incidence in stroke patients. 
4.3.2 Adverse Reactions 
Medically important ARs listed in the British National Formulary for antihypertensive 
and lipid lowering drugs will be recorded in the trial database, but not reported to 
regulatory authorities. It is important to record these ARs, since they will influence 
blood pressure and/or lipid management strategies as per the guiding algorithms.  
4.3.3 Serious Adverse Events (SAEs) related to Stroke 
Stroke and developing cognitive impairment are conditions with high morbidity and 
mortality, and several adverse events may occur during a patient’s participation in the 
trial. SAE’S that can be expected after stroke will be recorded in the trial database but 
not reported to regulatory authorities. A list is provided in a working practice 
document on the trial website. This list is a guide, and will be updated through the 
working practice document on the trial website.. Since most medical conditions can be 
described using a variety of descriptors, investigators should try, where possible, to 
match up SAE titles with the list below.  
4.3.4 Serious Adverse Reactions (SARs) 
As the trial is testing management strategies, not individual drugs, adverse reactions 
that are serious will be recorded on the trial database, but not reported to the 
regulatory authorities. 
4.3.5 Suspected Unexpected Serious Adverse Reactions (SUSAR) 
As the trial is testing management strategies, not individual drugs, and due to the 
long established nature of these drugs, SUSARs are not collected and recorded 
specifically, except as part of the recording of serious adverse reactions. However 
investigators are free to report adverse reactions/serious adverse reactions to national 
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agencies as they wish, e.g. through the Commission of Human Medicines Yellow Card 
pathway (www.yellowcard.gov.uk) in the UK. 
4.4 Serious Adverse Event (SAE) adjudication 
All SAEs will be recorded and monitored until resolution, stabilisation, or until it has 
been shown that the trial treatment is not the cause. Such SAEs should be completed 
within one week of investigators being aware of the event. Likely causality will be 
entered. 
For SAEs, the Chief Investigator and SAE adjudicator(s) shall: 
• Assess the event for seriousness, expectedness and relatedness to the trial 
treatment 
• Take appropriate medical action, which may include halting the trial and inform 
the Sponsor of such action 
• Make any amendments as required to the trial protocol and inform the REC as 
required 
4.5 Participant removal from the trial due to adverse events 
Any participant who experiences an AR or SAR may be withdrawn from treatment at 
the discretion of the Principal Investigator, or at the request of the participant. 
However there are usually alternative treatments for reducing blood pressure and 
lipids, which may be used instead of a particular drug causing an AR/SAR. Hence it 
should usually be possible to avoid withdrawing a participant from treatment. If 
patients do withdraw from treatment, ideally they should stay in the trial for the 
purposes of follow up. 
5 TRIAL MANAGEMENT 
5.1 Sponsor 
The University of Nottingham is the trial sponsor in the UK and will delegate 
responsibility for design and conduct of the trial to the Chief Investigator via our 
Sponsor/Chief Investigator agreement. The sponsor contact details are  
Mr Paul Cartledge 
Head of Research Grants and Contracts 
Research Innovation Services 
King’s Meadow Campus, Lenton Lane 
Nottingham, NG7 2NR 
UK 
5.2 Coordinating Centre 
The Stroke Trials Unit (STU), part of the University of Nottingham’s Clinical Trials Unit 
(which has provisional registration), will co-ordinate the trial. STU will have overall 
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responsibility for the conduct of the trial and will be responsible for provision of trial 
materials, collation and analysis of data and reporting of the final results. They will act 
as the International Coordinating Centre, UK National Coordinating Centre, the 
primary point of contact for UK centres, and the secondary point of contact for non-UK 
centres. 
Stroke Trials Unit 
Division of Stroke Medicine 
University of Nottingham 
Clinical Science Building 
City Hospital campus 
Nottingham, NG5 1PBUK 
Tel: +44 115 8231671 
Fax: +44 115 8230273 
5.3 Trial Steering Committee (TSC) 
The TSC will provide overall supervision, as per their charter, and ensure that the trial 
is conducted in accordance with the principles of the ICH GCP and the relevant 
regulations. Any amendments to the trial will be agreed by the TSC. The TSC will 
provide advice to the investigators on all aspects of the trial. The composition of the 
TSC is given on the Trial website. 
5.4 Data Monitoring Committee (DMC) 
The Data Monitoring Committee (DMC) will monitor efficacy and safety as per their 
charter. As well as outcome measures, the DMC will also review recruitment, baseline 
data, balance in baseline factors between the treatment group, completeness of data, 
compliance to treatment, co-administered treatments, and outcome by sub groups. 
They will also review all serious adverse events (both adjudicated and unadjudicated) 
and protocol violations. The DMC will usually meet at least yearly by teleconference; 
the chairman will receive 6 monthly updates from the statistician. The composition of 
the DMC is given on the Trial website. 
The Data Monitoring Committee charter will use similar stopping rules to those agreed 
and used in the MRC ENOS trial. (see section 6.6)) 
5.5 Outcome and event adjudication committees 
There will be 3 adjudication committees: 
• For cognitive decline and dementia 
• For stroke and other vascular events 
• For SAEs which do not relate to cognition of vascular events 
The committees will follow their respective charters. 
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6 ETHICAL AND REGULATORY ASPECTS 
6.1 Ethics Committee and regulatory approvals 
The trial will not be initiated before the protocol, informed consent forms, and 
participant and GP information sheets have received approval / favourable opinion 
from the UK Research Ethics Committee (REC), and the respective National Health 
Service (NHS) Research & Development (R&D) department. Should a protocol 
amendment be made that requires REC approval, the changes in the protocol will not 
be instituted until the amendment and revised informed consent forms and participant 
information sheets have been reviewed and received approval/favourable opinion 
from the REC and R&D departments. A protocol amendment intended to eliminate an 
apparent immediate hazard to participants may be implemented immediately 
providing that the REC are notified as soon as possible and an approval is requested. 
Minor protocol amendments only for logistical or administrative changes may be 
implemented immediately; and the REC will be informed. 
The trial will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, 1996; the principles of Good Clinical Practice 
(GCP), and the UK Department of Health Research Governance Framework for Health 
and Social care, 2005. 
The trial is supported by NIHR (National Institute of Health Research) Stroke Research 
Network, NIHR Primary Care Research Network and NIHR Dementia and 
Neurodegenerative Diseases Research Network. 
6.2 Informed consent and participant information 
The process for obtaining participant informed consent will be in accordance with REC 
guidance, GCP, and any other regulatory requirements that might be introduced. The 
investigator or their nominee and the participant shall both sign and date the 
Informed Consent Form before the person can participate in the trial. 
The participant will receive a copy of the signed and dated forms and the original will 
be retained in the Trial Master File. A second copy will be filed in the participant’s 
medical notes and a signed and dated note made in the hospital notes that informed 
consent was obtained for the trial. 
The decision regarding participation in the trial is entirely voluntary. The investigator 
or their nominee shall emphasise to them that consent regarding trial participation 
may be withdrawn at any time without penalty or affecting the quality or quantity of 
their future medical care, or loss of benefits to which the participant is otherwise 
entitled. No trial-specific interventions will be done before informed consent has been 
obtained. 
If the Informed Consent Form is amended during the trial, the investigator shall follow 
all applicable regulatory requirements pertaining to approval of the amended 
Informed Consent Form by the REC and use of the amended form (including for 
ongoing participants). 
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6.3 Records 
6.3.1 Case Report Form (CRF) 
Each participant will be assigned a trial identity code number, allocated at 
randomisation, for use on CRFs, other trial documents, and the electronic database. 
The documents and database will also use their initials (of first and last names 
separated by a hyphen or middle name initial when available) and age. 
CRFs will be treated as confidential documents and held securely in accordance with 
regulations. The investigator will make a separate confidential record, in a separate 
participant database, of the: participant’s name, date of birth, local hospital number 
or NHS number, address, telephone number, relative/friend’s contact details, and 
Participant Trial Number, to permit identification of all participants enrolled in the trial, 
so that follow-up may be performed. CRF access shall be restricted to those personnel 
approved by the Chief or local Principal Investigator and recorded on the ‘Trial 
Delegation Log’. 
All paper forms shall be filled in using black ballpoint pen. Errors shall be lined out, 
but not obliterated with correction fluid, and the correction inserted, initialled and 
dated. The Chief or Principal Investigator, or designate, shall sign a declaration 
ensuring accuracy of data recorded in the electronic-CRF through signing off database 
forms by the use of their Postal Index Number (PIN) code. 
6.3.2 Source documents 
Source documents shall be filed at the investigator’s site and may include, but are not 
limited to, consent forms, current medical records, laboratory results, and pharmacy 
records. A CRF may also completely serve as its own source data. Only trial staff as 
listed on the Delegation Log shall have access to trial documentation other than the 
regulatory requirements listed below. 
6.3.3 Scan Transfer and Storage 
• Baseline and subsequent clinical or research CT and/or MR brain scans should be 
sent electronically (ideally) using the secure internet webload facility provided on 
the PODCAST website (www.podcast-trial.org/). Scans should not be anonymised 
prior to upload as certain fields such as study date, birth date and sex are essential 
to ensure that the scan is matched to the patient. The upload facility will transfer 
data using RC4-MD5 (128 bit) cipher encryption and anonymise the DICOM header 
of the images automatically. The DICOM header attributes that are anonymised 
are a subset of those specified in the ‘Basic Application Level Confidentiality Profile’ 
of the DICOM standard 3.15; namely the institution name, institution address, 
referring physician, referring physician’s address, patient name, patient identifier, 
date of birth, other patient id, other patient names and patient’s address 
attributes.  
• If centres are unable to use the web upload facility, non anonymised scans can be 
copied on a CD/DVD with the data encrypted. The encrypted CD/DVD should be 
sent via recorded delivery to the PODCAST ICC. The password should be 
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communicated separately via email. The data will be unencrypted at the PODCAST 
ICC and uploaded to the database as described previously (see above)  
• If centres are unable to send the scans by the above methods, they will be advised 
to contact the PODCAST ICC, who will help them with the process.  
• Under exceptional circumstances, for centres where the only method of 
transferring images is by films/hardcopies, centres will be advised to send non 
anonysmised  films (this is essential as  the co-ordinating centre can ensure that 
the scans can be checked against patient details) via recorded delivery. These will 
be digitised and the resulting data anonymised.  
• All digital brain image data will be stored on secure computer servers owned and 
maintained by the Information Services, University of Nottingham, with access 
restricted both physically (locked server rooms) and by password. Access for 
adjudication, analysis and archiving will be by password.  
• Anonymised imaging data shall be adjudicated by trained neuroradiologists who 
may be based at the Coordinating Centre or elsewhere.  
• The systems have been designed to ensure the highest levels of data security and 
participant confidentiality, and will be further enhanced if future technological 
advances permit it. The enhancements to the current system may include the use 
of e-Science and Grid technologies (e.g. NeuroGrid, www.neurogrid.ac.uk/) if they 
prove to be superior to current systems. 
6.3.4 Direct access to source data and documents 
The CRF and all source documents, including progress notes and copies of laboratory 
and medical test results, shall made be available at all times for review by the Chief 
Investigator, PODCAST staff, Sponsor’s designee and inspection by relevant 
regulatory authorities. 
6.4 Data protection 
All trial staff and investigators will endeavour to protect the rights of the trial’s 
participants to privacy and informed consent, and will adhere to the UK Data 
Protection Act (1998). The CRF will only collect the minimum required information for 
the purposes of the trial. CRFs will be held securely, in a locked room, or locked 
cupboard or cabinet. Access to the information will be limited to the trial staff and 
investigators and relevant regulatory authorities (see above). Computer held data 
including the trial database will be held securely and password protected. All data will 
be stored on a secure dedicated web server. Access will be restricted by user 
identifiers, passwords and PINs (encrypted using a one way encryption method). 
Personal information (e.g. name and address of participants and secondary contacts) 
about trial participants will be held at local centres and will be passed onto the 
National Coordinating Centre and International Coordinating Centre (Nottingham UK). 
Participant information will be held on a database at the ICC but will be separated 
from all clinical information; the latter remain anonymous (identifiable only by initials, 
trial number and age). Computer data will be backed up regularly to an offsite secure 
repository (to enable disaster recovery). Personal participant information will be used 
only for the purposes of the PODCAST trial and will not be passed on to third parties. 
The personal participant information will be deleted within 12 months of the end of 
the trial. 
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Where permissible, the PODCAST ICC may use central databases to obtain additional 
follow-up information on participants enrolled into the trial. In the UK, this will involve 
use of the NHS Medical Research Information Service, Office of National Statistics 
(ONS) database. When information will be gathered on participants in this way, it will 
be clearly stated in the country specific patient/informant information sheets. 
Information about the trial in the participant’s medical records / hospital notes will be 
treated confidentially in the same way as all other confidential medical information. 
6.5 Quality assurance and audit 
6.5.1 Insurance and indemnity 
Insurance and indemnity for trial participants and local trial staff is covered within the 
UK NHS Indemnity Arrangements for clinical negligence claims in the NHS, issued 
under cover of HSG (96) 48.(52) There are no special compensation arrangements, 
but trial participants may have recourse through the NHS complaints procedures. 
The University of Nottingham has taken out an insurance policy to provide indemnity 
in the event of a successful litigious claim for proven non-negligent harm.  
6.5.2 Trial conduct 
Trial conduct will be subject to systems audit of the Trial Master File for inclusion of 
essential documents: 
• Permissions to conduct the trial 
• Trial Delegation Log 
• CVs of trial staff and training received 
• Local document control procedures 
• Consent procedures and recruitment logs 
• Adherence to procedures defined in the protocol (e.g. inclusion / exclusion 
criteria, correct randomisation, timeliness of visits) 
• Serious Adverse Event recording and reporting; accountability of trial materials 
and equipment calibration logs 
The Trial Coordinator, or where required, a nominated designee of the Sponsor, shall 
carry out a site systems audit, at least yearly, and an audit report shall be made to 
the Chief Investigator. 
6.5.3 Trial data 
Monitoring of trial data shall include: 
• Confirmation of informed consent – for all participants 
• Source data verification – use ROUNDUP SQR for calculating number of 
participants whose documents need to be monitored at centre (since last 
monitoring) 
• Data storage and data transfer procedures 
• Local quality control checks and procedures 
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• Back-up and disaster recovery of any local databases and validation of data 
manipulation 
The Trial Coordinator, or where required, a nominated designee of the Sponsor, shall 
carry out monitoring of trial data as an ongoing activity.  
Entries on CRFs will be verified by inspection against the source data. A sample of 
CRFs [ROUNDUP SQR (number of participants at centre since last monitoring)] will be 
checked on a regular basis for verification of all entries made. In addition, the 
subsequent capture of data on the trial database will be checked. Where corrections 
are required these will carry a full audit trail and justification. 
Trial data and evidence of monitoring and systems audits will be made available for 
inspection by REC as required. 
6.5.4 Record retention and archiving 
In compliance with the ICH/GCP guidelines, regulations and in accordance with the 
University of Nottingham’s Research Code of Conduct, the Chief or local Principal 
Investigator will maintain all records and documents regarding the conduct of the 
trial. These will be retained for at least 7 years after the end of the trial, or for longer 
if required. If the responsible investigator is no longer able to maintain the trial 
records, a second person will be nominated to take over this responsibility. 
The Trial Master File and trial documents held by the Chief Investigator on behalf of 
the Sponsor shall be finally archived at secure archive facilities at the University of 
Nottingham. This archive shall include all trial databases and associated meta-data 
encryption codes. 
6.6 Discontinuation of the trial by the sponsor 
The Sponsor reserves the right to discontinue this trial at any time for failure to meet 
expected enrolment goals, for safety or any other administrative reasons. The 
Sponsor shall take advice from the Trial Steering Committee, Data Monitoring 
Committee, and funder(s) as appropriate in making this decision. 
We will use a similar Data Monitoring Committee charter for electively stopping the 
trial that is agreed for the MRC ENOS trial. This states that: 
“During the period of recruitment into the study, the trial statistician will perform 
interim analyses on major outcome events and supply these, in strict confidence, to 
the members of the Data Monitoring Committee, along with any other analyses that 
the committee may request. In the light of these analyses, the Data Monitoring 
Committee will advise the Chairman of the Steering Committee and Chief Investigator 
if, in their view, the randomised comparisons in the trial have provided both: 
a. “Proof beyond reasonable doubt”† that for all, or for some, specific types of 
patient, treatment is clearly indicated or clearly contraindicated in terms of 
the primary outcome measure, and  
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b. Evidence that might reasonably be expected to influence materially the 
patient management of the many clinicians who are already aware of the 
results of any other relevant trials.  
The Steering Committee can then decide whether to modify intake to the trial (or to 
seek extra data). Unless this happens, however, the Steering Committee, the 
collaborators, and the central administrative staff (except those who produce the 
confidential analyses) will remain ignorant of the interim results. 
Collaborators, and all others associated with the trial, may write through the 
PODCAST office, Nottingham to the Chairman of the Data Monitoring Committee, 
drawing attention to any worries they may have about particular categories of patient 
requiring special consideration, or about any other matters that may be relevant. 
†Appropriate criteria of proof beyond reasonable doubt cannot be specified precisely, 
but a common view is that a difference of at least 3 standard deviations in an interim 
analysis of a major outcome event may be needed to justify halting, or modifying, 
such a study prematurely. If this criterion were to be adopted, it would have the 
practical advantage that the exact number of interim analyses would be of little 
importance, and so no fixed schedule is proposed. 
If a trial is discontinued for any of the above reasons, participants will go back to 
receiving standard care from their GPs. 
6.7 Statement of confidentiality 
Individual participant medical information obtained as a result of this trial is 
considered confidential and disclosure to third parties is prohibited with the exceptions 
noted above. 
Participant confidentiality will be further ensured by utilising identification code 
numbers to correspond to treatment data in the computer files. 
Such medical information may be given to the participant’s medical team and all 
appropriate medical personnel responsible for the participant’s welfare. 
Data generated as a result of this trial will be available for inspection on request by 
the participating physicians, the University of Nottingham representatives, the REC, 
local R&D Departments and the regulatory authorities. 
6.8 Publication and dissemination policy 
Data and results will be shared as follows: 
6.8.1 Presentation 
The main trial results will be presented to the investigators, and to funding bodies, 
and at major international and national scientific meetings, in the name of the trial 
and investigators i.e. ‘PODCAST Investigators’. 
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6.8.2 Publication 
The main results from the trial will be written by a ‘Writing Committee’ and published 
in quality peer-reviewed journal(s) in the name of the investigators, i.e. PODCAST 
Investigators. 
Secondary publications will be published as ‘Person(s), for the PODCAST 
Investigators’, where the person(s) are those who conceived, designed, or wrote the 
paper, or analysed and/or interpreted the data for the publication. 
Abstracts will be presented as ‘PODCAST Investigators, person(s)’, where the 
person(s) act as a contact point for the trial. 
Local investigators may present or publish data relating to their centre once the main 
trial findings have been published and following agreement by the Trial Steering 
Committee. 
6.8.3 Sharing of data 
Anonymised subsets of data may be shared with other research groups and projects 
(e.g. Cochrane Collaboration, OA-Cog) once the main trial findings have been 
published, and following agreement by the Trial Steering Committee. 
6.8.4 Management of post-trial BP and lipids 
Widespread presentation and publication of the results will allow participants and their 
general practitioners to discuss the most appropriate management for future control 
of BP and lipids. 
6.9 User and public involvement 
The trial has been reviewed, and is supported, by: 
• Alzheimer’s Society Quality Research in Dementia Consumer Advisory Network 
• UK Stroke Research Network Prevention Clinical Studies Group 
• Trent Stroke Consumer Group 
Several Participants/Carer Public Involvement (PCPI) representatives are on the Trial 
Steering Committee (see www.podcast-trial.org/). 
7  TRIAL FINANCES 
7.1 Funding sources 
The start-up phase is jointly funded by The Stroke Association UK and Alzheimer’s 
Society UK. Funding for the main phase will be sought mid-way through the start-up 
phase subject to the trial being considered feasible by the Trial Steering Committee 
and the Data Monitoring Committee. 
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The excess treatment costs and service support costs related to prescriptions and 
blood tests  have been derived by a multidisciplinary team (including a finance officer) 
involving representatives from the Trent CLRN (Comprehensive Local Research 
Network), Nottingham University Hospitals NHS Trust, Nottingham PCTs, The 
University of Nottingham, NIHR Stroke Research Network (through the Trent Local 
Research Network) and NIHR Primary Care Reserch Network. These were then 
submitted to the Department of Health for confirmation. The costing template is  
available to participating sites on the document repository of the NIHR CSP ReDa 
(National Institute for Health Research Coordinated System for obtaining NHS 
Permission Research Database)  
The excess treatment costs are part of government given PCT budgets and will be 
funded by the local Primary Care Trusts. The service support costs will be available 
through local CRLNs. 
7.2 Participant stipends and payments 
Participants will not be paid to participate in the trial. Travel or mileage/parking 
expenses will be offered for hospital visits. 
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8 SIGNATURE PAGES 
Signatories to Protocol: 
Chief Investigator: Professor Philip Bath 
Signature: __________________________________ 
Date: ___________ 
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APPENDICES 
Appendix A. Addenbrooke’s Cognitive Examination-Revised (ACE-R) 
The ACE-R will be modified to include death (thereby mimicking modification of 
functional outcome, e.g. Rankin Scale, to include death); participants who die will be 
assigned an ACE-R score of -1. 
ADDENBROOKE’S COGNITIVE EXAMINATION – ACE-R 
Name           : 
Date of birth : 
Hospital no.  : 
 
                                                        Addressograph 
Date of testing: ____/___/___  
Tester’s  name:_______________________ 
Age at leaving full-time education:________ 
Occupation:__________________________ 
Handedness:_________________________ 
 
ORIENTATION  
Ask: What is the 
 
Ask: Which  
 
Day  
________ 
Building 
________ 
Date 
________ 
Floor 
________ 
Month 
_________ 
Town 
________ 
Year 
_________ 
County   
________ 
Season 
_________ 
Country 
________ 
 
[Score0-5] 
 
[Score0-5] 
 
A + O 
REGISTRATION 
Tell: ‘I’m going to give you three words and I’d like you to repeat after me: lemon, key and ball’. 
After subject repeats, say ‘ Try to remember them because I’m going to ask you later’. Score 
only the first trial (repeat 3 times if necessary). 
Register number of trials ____ 
[Score0-3] 
 
 
A + O 
ATTENTION & CONCENTRATION 
Ask the subject: ‘could you take seven away from a hundred? After the subject responds, ask 
him or her to take away another 7 to a total of 5 subtractions. If subject makes mistake, carry on 
and check subsequent answerS (i.e 93,84,77,70,63- score 4) 
Stop after five subtractions (93, 86, 79, 72, 65). ____ ____ ____ ____ ____ 
Ask: ‘could you please spell WORLD for me? Then ask him/her to spell it backwards: 
      ____ ____ ____ ____ ____ 
[Score0-5] 
 
(for best 
performed 
task) 
A + O 
MEMORY- Recall  
Ask: ‘Which 3 words did  I ask you to repeat and remember?’ 
      __________     ________      ___________ 
[Score0-3] 
Mem
ory 
MEMORY– Anterograde Memory 
Tell: ‘ I’m going to give you a name and address and I’d like you to repeat after me. We’ll be 
doing that 3 times, so you have a chance to learn it because I’ll be asking you later’ Score only 
the third trial 
 1st Trial 2nd Trial 3rd Trial 
Harry Barnes 
73 Orchard Close 
Kingsbridge 
Devon 
 
_   _ 
_   _   _ 
_ 
_ 
_   _ 
_   _   _ 
_ 
_ 
_   _ 
_   _   _ 
_ 
_ 
[Score0 7] 
 
Memory 
MEMORY  Retrograde Memory  
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VERBAL FLUENCY - Letter ‘P’ and animals 
Letters 
Say: ‘I’m going to give you a letter of the alphabet and I’d like you to generate as 
many words as you can beginning with that letter, but not names of people or places. 
Are you ready? You’ve got a minute for that and the letter is letter P’  
[Score0  7] 
Fluen
cy 
>17 7 
14-17 6 
11-13 5 
8-10 4 
6-7 3 
4-5 2 
3-4 1 
<3 0 
total  
    
  
Animals 
Say: ‘Now let’s change. I’d like you to generate as many animals as possible, any kind 
of animal, beginning with any letter, it doesn’t matter’.  
[Score0 7] 
 
Fluency 
>21 7 
17-21 6 
14-16 5 
11-13 4 
9-10 3 
7-8 2 
5-6 1 
<5 0 
total  
    
  
L A N G U A G E  -  Comprehension 
 Show written instruction: [Score0-1] 
 
Language 
Close  your  eyes 
 
3 stage command: 
‘Take the paper in your right hand. Fold the paper in half. Put the paper on the floor’ 
 
[Score0-
3  
Language 
L A N G U A G E  - Writing  
Ask the subject to make up a sentence and write it in the space below: 
Score 1 if sentence contains a subject and a verb (see guide for examples) 
[Score0-
1] 
 
Language 
Name of current Prime Minister 
Name of the woman who was Prime Minister 
Name of the USA president 
Name of the USA president who was assassinated in the 1960’s  
[Score0-4] 
 
Memory 
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L A N G U A G E  -  Repetition 
Ask the subject to repeat:’ hippopotamus’; ‘eccentricity; ‘unintelligible’; ‘statistician’ 
Score 2 if all correct; 1 if 3 correct; 0 if 2 or less. 
[Score0-2] 
 
Ask the subject to repeat: ‘Above, beyond and below’                                                 [Score 0-1] 
 
Ask the subject to repeat: ‘No ifs, ands or buts’                                                 [Score 0-1] 
 
Language 
L A N G U A G E  -  Naming 
Ask the subject to name the following pictures 
: 
[Score 0-2] 
pencil + 
watch 
 
Language 
 
 
 
 [Score 0-10] 
  
Language 
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L A N G U A G E  -  Comprehension 
 
Using the pictures above, ask the subject to: 
Point to the one which is associated with the monarchy 
Point to the one which is a marsupial 
Point to the one which is found in the Antarctic 
Point to the one which has a nautical connection 
 
[Score0-4] 
 
Language 
LANGUAGE- Reading 
Ask the subject to read the following words: 
Sew 
Pint 
Soot 
Dough 
height 
 
[Score 0-1] 
 
Language 
VISUOSPATIAL ABILITIES  
Overlapping pentagons:  Ask the subject to copy this diagram: 
 
[Score0-1] 
 
Visuospatial 
 
 
Wire cube:  Ask the subject to copy this drawing (for scoring, see instructions guide) 
 
[Score 0-2] 
 
Visuospatial 
Confidential: PODCAST protocol, version 1.5, 28 February, 2012 
This protocol is confidential and the property of the University of Nottingham. No part of it may be 
transmitted, reproduced, published, or used by others persons without prior written authorisation from the 
University of Nottingham 
Page 51 of 75 
 
 
Clock:  Ask the subject to draw a clock face with numbers and the hands at ten past 
five. 
 
[Score 0-5] 
 
Visuospatial 
 
PERCEPTUAL ABILITIES 
Ask the subject to count the dots without pointing them Score 0-4] 
 
Visuospatial 
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PERCEPTUAL ABILITIES 
Ask the subject to identify the letters [Score 0-4]   
Visuospatial 
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RECALL  
Ask “Now tell me what you remember of that name and address we were repeating at the 
beginning”. 
Harry Barnes 
73 Orchard Close 
Kingsbridge 
Devon 
_   _ 
_   _   _ 
_ 
- 
[Score 0-7] 
Memo
ry 
 
RECOGNITION   
This test should be done if subject failed to recall one or more  items. If all items were 
recalled,skip the test and score 5. If only part  is recalled start by ticking items 
recalled in the shadowed column on the right hand side. Then test not recalled items 
by telling ‘OK, I’ll give you some hints: was the name X,Y or Z?” and so on. Each 
recognised item scores one point which is added to the point gained by recalling. 
[Score 0-5] 
 
Memory 
 
Jerry Barnes  Harry Barnes  Harry Bradford  recalled  
37  73  76  recalled  
Orchard Place  Oak Close  Orchard Close  recalled  
Oakhampton  Kingsbridge  Dartington  recalled  
Devon  Dorset  Somerset  recalled  
General Scores 
MMSE /30 
ACE-R /100 
Subscores 
Attention and Orientation /18 
Memory /26 
Fluency /14 
Language /26 
Visuospatial /16 
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Appendix B. Mini Mental state Examination (MMSE) 
The MMSE will be modified to include death (thereby mimicking modification of 
functional outcome, e.g. Rankin Scale, to include death); participants who die will be 
assigned a MMSE score of -1. 
No Question and Instructions Maximum 
Score 
Patient’s 
Score 
1 “What is the year?  Season?  Date?  Day of the week?  
Month?”  
 
5  
2 “Where are we now: State?  County?  Town/city?  
Hospital?  Floor?” 
5  
3 The examiner names three unrelated objects clearly 
and slowly, then  
asks the patient to name all three of them. The 
patient’s response is used for scoring. The examiner 
repeats them until patient learns all of them, if 
possible. Number of trials: ___________  
3  
4 “I would like you to count backward from 100 by 
sevens.” (93, 86, 79, 72, 65, …) Stop after five 
answers.  
Alternative: “Spell WORLD backwards.” (D-L-R-O-W)  
5  
5 “Earlier I told you the names of three things. Can you 
tell me what were they?” 
3  
6 Show the patient two simple objects, such as a 
wristwatch and a pencil, and ask the patient to name 
them.  
2  
7 “Repeat the phrase: ‘No ifs, ands, or buts.’” 1  
8 “Take the paper in your right hand, fold it in half, and 
put it on the floor.” (The examiner gives the patient a 
piece of blank paper.)  
3  
9 “Please read this and do what it says.” (Written 
instruction is “Close  your eyes.”)  
1  
10 “Make up and write a sentence about anything.” (This 
sentence must contain a noun and a verb.)  
1  
11 “Please copy this picture.” (The examiner draws a 
picture of intersecting pentagons and gives the 
patient a blank piece of paper and asks him/her to 
copy the picture. All 10 angles must be present and 
the two pentagons must intersect.)   
1  
12 Total Score 30  
See (3) 
 
 
 
Confidential: PODCAST protocol, version 1.5, 28 February, 2012 
This protocol is confidential and the property of the University of Nottingham. No part of it may be 
transmitted, reproduced, published, or used by others persons without prior written authorisation from the 
University of Nottingham 
Page 55 of 75 
Appendix C. telephone version of MMSE (t-MMSE) 
QUESTIONS Maximum 
score 
Patient’s 
score 
What is the year/ season/date/day/month? 5  
Where are we now- building/city/county/country? 4  
I am going to name three objects and I want you to repeat it 
after me. They are apple, table and coin. Please repeat them 
3  
Can you subtract 7 from 100 (93,86,79,72,65) 5  
Can you recall the three words I asked you to remember 3  
Can you repeat “No ifs, ands  or  buts” 1  
Tell me what is the thing called that you are speaking into as 
you talk to me 
1  
Total score 22  
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Appendix D. Telephone Instrument for Cognition Scale-M 
Please note that this test is designed for telephone use. In the event follow up is done 
in person the entire test must be completed verbally, i.e. the memory words must not 
be shown to the participant. Score 1 point for each correct answer. 
Question and Instructions Score 
Orientation: Please ask them what day, date etc it is 7 
Day 
Date 
Month 
Season 
Year 
Age 
Telephone Number (code+number) 
! 
! 
! 
! 
! 
! 
Registration 10 
I am going to read you a list of 10 words. Please listen carefully and try to remember 
them. When I am done, tell me as many as you can in any order. Ready? 
Cabin 
Pipe 
Elephant 
Chest 
Silk 
Theatre 
Watch 
Whip 
Pillow 
Giant 
! 
! 
! 
! 
! 
! 
! 
! 
! 
! 
 
Attention and Calculation 6 
Please take away 7 from 100. Now continue to take 7 away from what you have left 
over until I ask you to stop 
93 
86 
79 
72 
65 
! 
! 
! 
! 
! 
Count backwards Please count back 20-1 
No mistakes ! 
Comprehension, Semantic and Recent Memory 5 
What do people use to cut paper?  
What is the prickly green plant found in the 
desert?  
Who is the Prime Minister? 
Who is the reigning monarch?  
What is the opposite direction to east? t 
Scissors 
Cactus 
 
Correct surname 
E,QE,QE2 
West 
! 
! 
 
! 
! 
! 
Language/Repetition   
Please listen carefully and repeat No ifs ands or buts’                        
1 
! 
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Score only if exactly right 
Delayed Recall 10 
Please repeat as many of the 10 words I asked you to remember earlier 
 
Cabin 
Pipe 
Elephant 
Chest 
Silk 
Theatre 
Watch 
Whip 
Pillow 
Giant 
 
! 
! 
! 
! 
! 
! 
! 
! 
! 
! 
 
Total Score (1 point for each correct answer) 
 
  /39 
 
See (53) 
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Appendix E. Trail Making Test (TMT) Parts A &B 
Instructions 
Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of 
paper. In Part A, the circles are numbered 1 – 25, and the participant should draw 
lines to connect the numbers in ascending order. In Part B, the circles include both 
numbers (1 – 13) and letters (A – L); as in Part A, the participant draws lines to 
connect the circles in an ascending pattern, but with the added task of alternating 
between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The participant should be 
instructed to connect the circles as quickly as possible, without lifting the pen or pencil 
from the paper. Time the participant as he or she connects the "trail." If the 
participant makes an error, point it out immediately and allow the participant to 
correct it. Errors affect the participant's score only in that the correction of errors is 
included in the completion time for the task. It is unnecessary to continue the test if 
the participant has not completed both parts after five minutes has elapsed.  
Step 1: Give the participant a copy of the Trail Making Test Part A worksheet and a 
pen or pencil.  
Step 2: Time the participant as he or she follows the “trail” made by the numbers on 
the test.  
Step 3: Record the time.  
Step 4: Repeat the procedure for Trail Making Test Part B.  
Scoring: 
Results for both TMT A and B are reported as the number of seconds required to 
complete the task; therefore, higher scores reveal greater impairment.  
Average Deficient Rule of Thumb  
Trail A 29 seconds > 78 seconds Most in 90 seconds  
Trail B 75 seconds > 273 seconds Most in 3 minutes  
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Appendix F. Modified Rankin Scale (mRS) 
0 No symptoms at all 
1 No significant disability, despite symptoms; able to carry out all usual duties 
and activities 
2 Slight disability; unable to carry out all previous activities but able to look after 
own affairs without assistance 
3 Moderate disability; requiring some help, but able to walk without assistance 
4 Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent and requiring constant nursing care 
and attention 
6 Dead 
Score out of 6 (range 0-6) 
See (13, 14) 
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Appendix G. Barthel Index (BI) 
Task Criteria Score 
Bowels Incontinent 
Occasional accident (once per week) 
Continent 
 
0 
5 
10 
Bladder Incontinent, or catheterised and unable to manage 
alone 
Occasional accident (maximum once per 24 hours) 
Continent 
 
0 
5 
10 
Grooming Needs help with personal care 
Independent face/hair/teeth/shaving (implements 
provided) 
 
0 
5 
Toilet use Dependent 
Needs some help, but can do something alone 
Independent (on and off, dressing, wiping) 
 
0 
5 
10 
Feeding Unable 
Needs help cutting, spreading butter, etc. 
Independent 
 
0 
5 
10 
Transfer (bed to 
chair and back) 
Unable, no sitting balance 
Major help (one or two people, physical), cab sit 
Minor help (verbal or physical) 
Independent 
 
0 
5 
10 
15 
Mobility Immobile 
Wheelchair independent, including corners 
Walks with help of one person (verbal or physical) 
Independent (but may use any aid: for example stick) 
 
0 
5 
10 
15 
Dressing Dependent 
Needs help but can do about half unaided 
Independent (including buttons, zips, laces, etc.) 
 
0 
5 
10 
Stairs Unable 
Needs help (verbal, physical, carrying aid) 
Independent 
 
0 
5 
10 
Bathing Dependent 
Independent (or in shower) 
 
0 
5 
Total Score  /100 
See (14, 15) 
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Appendix H. EuroQoL 
By placing a tick in one box in each group below, please indicate which statements 
best describes your own health state today.  
Mobility 
 
Tick appropriate box 
I have no problems in walking about 
 
! 
I have some problems in walking about 
 
! 
I am confined to bed 
 
! 
Self-Care 
 
I have no problems with self care 
 
! 
I have some problems with washing or dressing 
 
! 
I am unable to wash or dress myself 
   
! 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
 
I have no problems performing my usual activities  
 
! 
I have some problems performing usual activities 
 
! 
I am unable to perform my usual activities 
 
! 
Pain/Discomfort 
 
I have no pain or discomfort 
 
! 
I have moderate pain or discomfort 
 
! 
I have extreme pain or discomfort 
 
! 
Anxiety/Depression 
 
I am not anxious or depressed 
 
! 
I am moderately anxious or depressed 
 
! 
I am extremely anxious or depressed 
 
! 
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EUROQOL-VAS 
We would like you to indicate on this scale how good or bad your own health is today, in your 
opinion. Please do this by drawing a line from the box below to whichever point on the scale 
indicates how good or bad your health state today is. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See (10) 
                                                                                                                                                                                                                                                                                                                                                                                                                
100 
90 
80 
70 
60 
50 
30 
40 
20 
10 
Your own 
health state 
today 
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Appendix I: Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE) 
We want you to remember what your friend or relative was like during the last follow-
up and to compare it with what he/she is like now. The last follow-up was in 20__. 
Below are situations where this person has to use his/her memory or intelligence and 
we want you to indicate whether this has improved, stayed the same, or got worse in 
that situation over the past 1 year. Note the importance of comparing his/her present 
performance with the last follow-up. So if during the last follow-up this person always 
forgot where he/she had left things, and he/she still does, then this would be 
considered 'Hasn't changed much’. Please indicate the changes you have observed by 
circling the appropriate answer. 
Compared with the last follow-up how is this person at: 
 1 2 3 4 5 
1. Recognizing the faces 
of family and friends 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
2. Remembering the 
names of family and 
friends 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
3. Remembering things 
about family and friends 
e.g. occupations, 
birthdays, addresses 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
4. Remembering things 
that have happened 
recently 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
5. Recalling 
conversations a few 
days later 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
6. Forgetting what 
he/she wanted to say in 
the middle of a 
conversation 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
7. Remembering his/her 
address and telephone 
number 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
8. Remembering what 
day and month it is 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
9. Remembering where Much A bit Not A bit Much worse 
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things are usually kept 
 
improved improved much 
change 
worse 
10. Remembering where 
to find things which 
have been put in a 
different place from 
usual 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
11. Adjusting to any 
change in his/her day-
to-day routine 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
12. Knowing how to 
work familiar machines 
around the house 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
13. Learning to use a 
new gadget or machine 
around the house 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
14. Learning new things 
in general 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
15. Remembering things 
that happened to 
him/her when he/she 
was young 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
16. Remembering things 
he/she learned when 
he/she was young 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
17.Understanding the 
meaning of unusual 
words 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
 
18.Understanding 
magazine or newspaper 
articles 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
 
19.Following a story in a 
book or on TV 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
 
20. Composing a letter 
to friends or for 
business purposes 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
21. Knowing about 
important historical 
events of the past 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
22. Making decisions on Much A bit Not A bit Much worse 
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everyday matters improved improved much 
change 
worse  
23. Handling money for 
shopping 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
 
24. Handling financial 
matters, e.g. the 
pension, dealing with 
the bank 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
 
25. Handling other 
everyday arithmetic 
problems, e.g. knowing 
how much food to buy, 
knowing how long 
between visits from 
family or friends 
 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
 
26. Using his/her 
intelligence to 
understand what's going 
on and to reason things 
through 
Much 
improved 
A bit 
improved 
Not 
much 
change 
A bit 
worse 
Much worse 
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Appendix J. Zung Depression rating Scale (short) 
The next set of questions is asking about your mood and how you feel in yourself. 
Answer these questions by placing a tick in each group below. Please indicate which 
mood describes you best today. 
 Seldom or  
never 
Some of 
the time 
Good part 
of the time 
Most of 
the time 
I feel down-hearted and blue ! ! ! ! 
 
Morning is when I feel  best ! ! ! ! 
 
I  have  trouble sleeping at night ! ! ! ! 
 
I can eat as much as  I used to ! ! ! ! 
 
I get tired for no reason ! ! ! ! 
 
I find it difficult to make decisions ! ! ! ! 
 
I feel hopeful about the future ! ! ! ! 
 
I feel that I am useful and needed ! ! ! ! 
 
My life is some what empty ! ! ! ! 
 
I still enjoy the things I used to 
do 
! ! ! ! 
 
 
Short Zung IDS Index = 100 x Total / 40 
Depression > 70 
See (12, 14, 54) 
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Appendix K Definitions 
Acute Stroke Unit 
A high-dependency nursing unit (or area) caring only/mainly for participants with 
acute stroke and providing close monitoring of neurological and vascular signs. 
Bleeding 
Major bleed 
These will constitute a serious adverse event. 
Fatal bleeding, and/or 
Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment syndrome, and/or 
Bleeding causing fall in haemoglobin of 2 g/l (1.24 mmol/l) or more, or leading to 
transfusion of 2 or more units of whole blood or red cells. 
Moderate bleed 
Not major, and 
Bleeding causing fall in haemoglobin of 1-2 g/l, and leading to no transfusion, or 
transfusion of only 1 unit of whole blood or red cells. 
Minor bleed 
Not major or moderate, and 
Comprising bruising, ecchymoses, gingival bleed or similar other type bleeding. 
Bleeding on CT/MRI head scans: 
Haemorrhagic Infarct (HI) 
Petechial infarction without space occupying effect. 
HI1 - small petechiae 
HI2 - more confluent petechiae 
Parenchymal Haemorrhage (PH) 
Haemorrhage with mass effect. 
PH1 - <30% of the infarcted area with mild space occupying effect 
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PH2 - >30% of the infarcted area with significant space occupying effect 
Cognitive decline 
A reduction in the ACE-R of <10 points or to <70(2). 
Cognitive impairment 
ACE-R score 70 points or lower. 
Dementia 
As defined by DSM IV 
1. Impairment of two or more of the following areas of cognition, sufficient to 
interfere with work, social function, or relationships: 
Memory 
Language 
Abstract thinking and judgement 
Praxis 
Visuospatial or perceptual skills 
Personality 
Social conduct 
2. The absence of the features of delirium 
3. The exclusion of non-organic psychiatric disorders, for example major depression 
or schizophrenia. 
See (55) 
Disposition 
Home, institution (e.g. warden controlled; nursing home), dead 
Muscle Problems related to statins 
We will define muscle problems related to statins as per the ACC/AHA/NHLBI advisory 
on the use and safety of statins(56). 
Myalgia : muscle ache or weakness without creatine kinase (CK) elevation. 
Myositis : muscle symptoms with increased CK levels. 
Rhabdomyolysis : muscle symptoms with marked CK elevation (typically >10 times 
upper limit of normal) and creatinine elevation (usually with brown urine and urine 
myoglobin). 
Neurological deterioration 
A reduction in NIHSS of > 4 points, or decrease in consciousness level by > 3 points, 
as compared with baseline. 
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Informant (consultee) 
A partner, sibling, child, or friend who is willing and able to attend clinics with the 
participant and who will provide structured information about the participant. 
Recurrent stroke 
Classified as haemorrhagic or ischaemic (if documented by CT scan or autopsy), or of 
unknown type. The time from stroke onset and side will be noted.  
Significant hypotension 
A symptomatic fall in blood pressure of >20% as compared with baseline 
necessitating intervention with cessation or weaning of BP drugs. 
Statin Classification (‘guideline’ statins and ‘intensive’ statins) 
‘Guideline’ statins: Simvastatin ! 40 mg, any dose of Pravastatin or Fluvastatin, 
Atorvastatin !20 mg, 
‘Intensive’ statins: Atorvastatin >20 mg, Rosuvastatin 
Stroke Rehabilitation Unit 
A dedicated rehabilitation unit (or area) caring only/mainly for participants with recent 
stroke and providing multi-disciplinary therapy (e.g. physiotherapy, occupational 
therapy, speech & language therapy). 
Stroke 
A clinical syndrome characterised by rapidly developing clinical symptoms and/or 
signs of focal (and at times global) loss of cerebral function with symptoms lasting for 
more than 24 hours or leading to death, with no apparent cause other than that of 
vascular origin’.(57) 
Transient Ischaemic Attack (TIA) 
A sudden focal neurological deficit of the brain or eye, presumed to be of vascular 
origin and lasts less than 24 hours.  
Symptomatic intracranial haemorrhage 
Neurological deterioration (see above), or death, and intracranial haemorrhage (of PH 
type) found on CT scan or autopsy. See (58) 
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